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ABSTRACT
Current methods for protein identification in tandem mass spectrometry (MS/MS) involve
database searches or de novo peptide sequencing, with database searches being the stan-
dard method. With database searches, issues arise when the species is not in the database.
Shortcomings of de novo peptide sequencing and database searches include chemical noise,
overly complex fragments, and incomplete b and y ion sequences. Here we present a
Bayesian approach to identifying peptides. Our model uses prior information about the
average relative abundances of bond cleavages and the prior probability of any particular
amino acid sequence. The proposed likelihood function is composed of two overall dis-
tance measures, which measure how close an observed spectrum is to a theoretical scan
for a peptide. A Markov chain Monte Carlo (MCMC) algorithm is employed to simulate
candidate choices from the posterior distribution of the peptide sequence. The true pep-
tide is estimated as the peptide with the largest posterior density. In addition, our method
is designed to rank top candidate peptides according to their approximate posterior den-
sities, which allows one to see the relative uncertainty in the “best” choice. A simulation
study was carried out to ensure our algorithm is performing accurately. Two different noise
structures were explored: a Laplace noise structure and a Poisson noise structure. Sim-
ulation studies showed our methods are promising. Our motivating data come from the
Pacific Northwest National Laboratory (PNNL) and the dataset is from the salmonella ty-
phimurium species. The dataset is a set of doubly charged tryptic peptides. When our
method was applied to peptides from this dataset, the true peptide was captured among the
list of the top estimated peptides.
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Proteomics is a vast analysis of proteins, particularly their structure, function, abundances,
and variations and modifications. In proteomics, scientists begin with the protein and work
backwards to determine the gene that is responsible for its production. Arguments can be
made for studying proteins as opposed to mRNA or DNA. Proteins are constantly changing
and vary with health or disease while a genome remains relatively static. Also, according
to Morris et al. (2010) “Proteins are more relevant to the biological function of the cell,”
and proteomic tests can be carried out on serum and urine, which can be obtained quickly
and effortlessly, unlike mRNA or DNA (Morris et al., 2010). In clinical proteomics, scien-
tists commonly search for proteins or groups of proteins to help diagnose types of cancers,
diseases, or viruses with the goal of early diagnosis. These proteins or groups of proteins
can be biomarkers for a disease; see Wulfkuhle et al. (2003), Diamandis (2004), and Vis-
intin et al. (2008). Currently, many of the drugs today work well by targeting proteins, or
these drugs are actually proteins themselves. With more advances in proteomics, scientists
hope eventually to develop drugs that are made specifically for an individual in order for
the drug to be more effective with fewer side effects.
Issues arise in protein identification when an organism’s genome has not been se-
quenced, more specifically in microbial samples. Only 1%-10% of microbes found in
the ecosystem can be cultured. There are countless other microbes that have not been
identified and, of the microbes that have been cultured, some will show evidence of post
translational modifications. These post translational modifications cannot be calculated
from the genome (Rose et al., 2010). There has been little progress in the area of envi-
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ronmental proteomics. Since only 1%-10% of all microbes can be cultured, being able to
correctly identify these microbes via protein identification is of great importance especially
in ecological samples such as soil and water samples (Schulze, 2004). Correctly identifying
proteins will also aid in the advance of clinical proteomics.
Current methods for identification of proteins are lacking. With a limited number of
known genome sequences, noisy data, and incomplete ion sequences, the accuracy of pro-
tein identification is limited. In this thesis, we describe a Bayesian approach which aims to
improve the identification of proteins.
1.1 PROPOSED WORK
We employ a Bayesian stochastic search approach to protein identification. We use the
prior knowledge of abundances of bond cleavages and the probability of any particular
amino acid sequence. The likelihood function combines two measures of distance that
measure the closeness of each observed m/z value to an m/z value in a theoretical scan of
a peptide. An MCMC scheme is utilized to simulate candidate peptides from the posterior
distribution, and the peptide with the largest posterior probability is estimated as the true
protein. Our approach also allows one to rank the top candidate peptides by their estimated
posterior probabilities.
The data comes from the Pacific Northwest National Laboratory (PNNL) and can be
publicly accessed online for download (Ansong et al., 2011). This dataset is produced by a
LTQ Orbitrap yielding doubly charged tryptic peptides. For each peptide, there is a set of
m/z values with corresponding intensity values. Figure 1.1 pictorially shows the spectrum
for a given spectrum by plotting them/z values versus their corresponding intensity values.
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Figure 1.1 Line plot of pairs of intensities and m/z values for a given peptide.
1.2 OVERVIEW OF THESIS
The thesis is arranged as follows. Chapter 2 describes how one obtains the proteomic pro-
file of a sample and provides insight on current methods for identifying proteins. Chapter 3
introduces basic concepts of peptide fragmentation and the construction of a peptide’s the-
oretical spectrum. Chapter 4 describes our proposed method. Section 4.2 explains our like-
lihood function. Section 4.3 illustrates the prior knowledge we incorporate into our model
and Section 4.4 defines the posterior density. Chapter 5 discusses in detail the Markov
chain Monte Carlo algorithm. Chapter 6 illustrates the precision of our method via simu-
lation and Chapter 7 provides a demonstration of our method with a real data application.
Chapter 8 concludes the thesis.
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CHAPTER 2
MASS SPECTROMETRY AND PROTEIN IDENTIFICATION
METHODS
2.1 MASS SPECTROMETRY
There are several methods for obtaining the proteomic profile of a sample. Developed in
the 1970s, 2-d gel electrophoresis (2DE) is one of the oldest technologies to identify the
proteomic profile. With technological advances, mass spectrometry methods are now more
commonly used. In 2DE, proteins from two different samples are analyzed and then the
patterns in the proteins are compared. Protein spots that are of interest are then removed
from the gel and absorbed by proteolytically or chemically producing peptides that are to
be analyzed via mass spectrometry (Issaq et al., 2003).
Matrix-assisted laser desorption and ionization - time of flight mass spectrometry (MALDI-
TOF) and surfaced-enhanced laser desorption and ionization mass spectrometry (SELDI-
TOF) are two types of mass spectrometry methods. In MALDI-TOF, the proteomic sample
must first be mixed with an energy absorbing matrix (EAM). The mixture is then crys-
tallized onto a metal plate. SELDI-TOF includes further chemistry on the target surface
of the metal plate, which keeps proteins from complex mixtures according to the distinct
properties of the proteins. The metal plate is then placed into a vacuum chamber where
the crystallized mixture is hit with pulses from a nitrogen laser. The matrix crystallized
molecules consume energy that is produced from the laser and transfer it to the proteins.
This causes the proteins to be desorbed and ionized, which creates ions in the gas phase.
This process occurs in the presence of an electric field. The electric field speeds up the ions
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Figure 2.1 A simplified representation of the MALDI-TOF method reproduced by
Radboud University Nijmegen (2013).
into a flight tube where the ion hits a detector, which records the time it takes the ion to fly
through the tube and strike the detector (Coombes et al., 2007; Issaq et al., 2003). Figure
2.1 provides a simplified illustration of the MALDI-TOF method.
Peaks can be identified by plotting the intensities versus a horizontal index. These
peaks characterize the peptide in the current sample. The horizontal index predominantly
used in proteomic analysis is the particle’s mass-to-charge ratio (m/z). Thus, one can plot
the intensities versus the mass-to-charge ratio. In mass spectrometry methods, the m/z
value from the time of flight is computed by using a quadratic transformation. To establish
the coefficients for the quadratic transformation, a small number of molecules (usually
between 3 and 7) with known masses are used to generate a spectrum. Then a count of
peaks analogous to the known masses in the spectrum is obtained. Given the set of (time,
mass) pairs, the method of least squares determines the coefficients. These calculations are
carried out in a preprocessing stage, and the final data spectrum is the line plot of pairs of
intensities and m/z values (Coombes et al., 2007).
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Figure 2.2 This figure, taken from Antoniewicz (2013), shows a simplified
representation of how a triple quadrupole mass spectrometer works. Abbreviations: gas
chromatography (GC); liquid chromatography (LC); electron impact ionization (EI);
electrospray ionization (ESI); first, second, and third quadrupole (Q1, Q2, and Q3).
2.2 TANDEM MASS SPECTROMETRY
Tandem mass spectrometry (MS/MS) is a two-stage mass spectrometry process that al-
lows examination of individual ion fragmentation from a group of ions. Figure 2.2 provides
a simplified diagram of how a triple quadrupole mass spectrometry works. Tandem mass
spectrometry is used with an assortment of instruments and scan modes. There are two key
types of instruments used. The first type is an instrument in which two mass spectrometers
are assembled in tandem that uses a sequence of mass spectrometers in space, where “in
space” means that there is a physical separation of the instrument components. The sec-
ond type of instrument contains analyzers that store ions where one spectrometer with ion
capability assigns a sequence of events in time. The most commonly used tandem mass
spectrometer is the triple quadrupole. In a triple quadrupole mass spectrometer, the first
and second quadrupole are mass analyzers while the second quadrupole allows ions of any
mass to pass through. Figure 2.3 shows a graphical diagram of a triple quadrupole mass
spectrometer. A quadrupole mass analyzer is composed of four cylindrical rods that are set
parallel to each other. When used in mass spectrometry, the quadrupole is the integral part
of the instrument that filters the sample ions based on their m/z values.
There are three scan types that are commonly used: the product ion, precursor ion, and
neutral loss scans, where the product ion scan is used most often. In a product ion scan,
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Figure 2.3 This figure, taken from de Hoffmann (1996), shows a schematic diagram of a
triple quadrupole mass spectrometer.
Figure 2.4 This figure, taken from de Hoffmann (1996), graphically shows the
difference between the three scan types. MS1 refers to the first mass spectrometer and
MS2 refers to the second mass spectrometer.
ions of a specific m/z value are selected in the first mass spectrometer and are analyzed in
the second mass spectrometer resulting in a product ion spectrum. In a precursor ion scan,
the second mass spectrometer only allows ions with a given m/z value to pass through.
The first mass spectrometer, which contains a collision gas, is then scanned over a preset
mass range detecting only ions that produce the pre-selected product ion. In a neutral loss
scan, the first mass spectrometer scans all the masses while the second mass spectrometer
still scans but at a certain offset value from the first mass spectrometer, where the offset
value corresponds to a neutral loss that is typically observed for that class of compounds
(de Hoffmann, 1996). Figure 2.4 illustrates pictorially the distinction between the three
scan modes.
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High performance liquid chromatography (HPLC) joined with mass spectrometry is a
more recent method for proteomic profiling. HPCL is a separation approach comprising
the mass-transfer between the liquid mobile phase and the stationary phase, which could
be a solid or a liquid (Standardbase-Techniques, 2012). Although these methods differ in
the way they obtain the proteomic profile, they are all extremely sensitive tools.
2.3 PROTEIN IDENTIFICATION METHODS
Presently, there are few methods for identifying protein sequences. A popular approach
searches through a database of peptides and then matches the closest peptide using the
observed spectrum. Some common algorithms for database searches are SEQUEST and
MASCOT. Another common approach is de novo sequencing, in which the peptide se-
quence is determined by recreating a spectrum using the observed spectrum. PepNovo and
Peaks are frequently used de novo algorithms. A more recent approach uses a mixture of
the other two. In this approach, the de novo method recaptures short peptide sequences and
then the peptide sequences are used to refine the search in the database approach (Frank
and Pevzner, 2005).
PepNovo is the more commonly used de novo sequencing approach. A scoring function
allows one to examine the spectral matches of the candidate peptide and observed spectrum.
PepNovo offers two types of scoring methods that typically use a tolerance of 0.5 Da when
identifying the ion fragmentation.
The most commonly used score is the ranking score, which is a machine learning rank-
ing algorithm. A discriminative boosting-based method for scoring models was developed
by Frank (2009). Their model depends upon a large set of distinct feature functions that
compute different qualities of peptide-spectrum matches (PSMs). The method optimizes
the models of the PSMs results by differentiating between the correct and incorrect results
of the PSMs. Here the boosting-based RankBoost algorithm developed by Freund et al.
(2003) is used in the discriminative ranking approach to scoring PSMs. The RankBoost
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algorithm is used to train the ranking-based model, which employs a machine learning
method called boosting. Several inputs must be supplied to the RankBoost algorithm. The
first input is an instance space. When using the rank score method in PepNovo, the in-
stance space is a training set of PSMs from the PepNovo score, which is explained in the
next paragraph. The second input is an ordering of the instances from the training set. The
last input is a set of feature functions such as the spectrum graph feature and peak anno-
tation features. The purpose of the RankBoost learning algorithm is to compute a ranking
function that assigns correct PSMs a higher score than incorrect ones. See Freund et al.
(2003) for more details about the RankBoost algorithm and see Frank (2009) for more de-
tails about the feature functions. The discriminative boosting-based method is applied to
the PepNovo score results and yields the rank score. The peptide with the highest rank is
the best estimate for the true peptide (Frank, 2009).
The PepNovo score is another scoring method, which breaks down a probabilistic net-
work in order to develop a better model for peptide fragmentation. Here the objective of
the de novo sequencing is to find the peptide that maximizes P (S|P ) across all viable
candidate peptides where S is the observed spectrum and P is the peptide. There are two
continuous values, intensities and cleavage positions, which must be discretized in order
to use this scoring method. Due to the fact that the sizes of intensities can be extremely
different, k discrete relative intensity levels are assigned to the peaks. A normalized inten-
sity is found by dividing each peak’s intensity by the baseline intensity. This baseline is
found by averaging the intensities of the weakest 33% of the peaks in the spectrum. Frank
and Pevzner (2005) found that k = 4 yields the best results. Now the relative cleavage
position, pos(m), is discretized into 5 equally sized regions. Here pos(m) is defined as
pos(m) = m/PM where m is the position of the cleavage site and PM is the mass of the
peptide. A likelihood ratio test is utilized for each prefix mass m of a peptide to show how
likely there is to be a cleavage of a peptide at mass m. The peptide prefix masses are the
possible cleavage sites, which are the vertices in the spectrum graph. The likelihood ratio
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test is composed of two hypothesis tests. The first hypothesis is the collision-induced disso-
ciation (CID) hypothesis. This hypothesis assumes that m is a true cleavage in the peptide
that produced the observed spectrum. A probabilistic network is employed to determine
the probability PCID(~I,m) of identifying an experimental series of fragment intensities ~I
given that the prefix mass is a cleavage site in the peptide that produced the observed spec-
trum. The second hypothesis is the random peaks hypothesis. This hypothesis assumes the
peaks in the observed spectrum are created by a random process and thus the intensities ~I
that correspond to the fragmented ions are assumed to be random. Since each peak is dis-
persed independently, the probability PRandom(~I,m) is the product of the probabilities of
observing the individual peaks in their bins. See Frank and Pevzner (2005) for more details
on the CID hypothesis, the random peak hypothesis and spectrum graphs. The logarithm
of the likelihood ratio test for a given prefix mass can be defined as




where a positive score indicates that the peak intensities, ~I , were more likely caused by a
true cleavage in the peptide and a negative score indicates that the peak intensities, ~I , are
more likely to due to random peaks. To obtain the overall score for a peptide, one needs to





where P is the candidate peptide. The peptide with the largest score is chosen as the best
estimate of the true peptide (Frank and Pevzner, 2005).
Unlike PepNovo and other less common approaches, PEAKS does not convert the spec-
trum into a graph, but works directly with the spectrum. PEAKS first preprocesses the raw
data by reducing the noise and centering the peaks. Since PEAKS works directly with the
spectrum, this step is quite important. A score for each mass value is computed for a y
and b ion according to the peaks near them. If there are missing peaks for a particular
y and b ion pair, a penalty score is given. Next, the set of the 10000 best sequences of
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all combinations of amino acids that maximizes the total scores is found. Then the set of
10000 sequences are evaluated further using a more precise scoring function. Finally, a
confidence score for each top scoring peptide is produced, and a confidence level for each
amino acid residue in the set of top scoring peptides is computed. In a newer version, these
sequences are then used to choose promising proteins from a database of proteins based
on sequence similarity. Using the same scoring function as the de novo sequencing, each
spectrum is compared with all the peptides chosen from the potential proteins (Ma et al.,
2003).
In de novo sequencing algorithms, it is important to be able to classify ions correctly
and then select informative ions from the observed spectrum to recreate the spectrum in
order to identify the peptide. Cleveland and Rose (2012) use a leveraged Bayesian neural
network to better classify ions, which leads to better identification of peptides. The details
of their work are discussed in more detail in Chapter 8.1.
MASCOT is the most regularly used database protein identification approach. The
scoring function that is employed in MASCOT is a molecular weight search (MOWSE),
which assesses the match between the observed spectrum and a known peptide. It is as-
sumed that the matches between the peaks of the observed spectrum and the fragmented
ions from known peptides are random, and the probability that the matches occur randomly
is computed. If the observed spectrum is aligned with the correct peptide, this probability
will be extremely small because the peaks in the observed spectrum will match up with the
peptide. The scoring function MOWSE only yields scores that indicate the significance of
a match. The peptide with the highest score is then chosen as the estimated peptide. In
order to get a better understanding of how correct the match is, the score is compared with
other peptides.
SEQUEST is another database protein identification approach, which uses a cross-
correlation scoring function. Like MASCOT, the scoring function assesses the match be-
tween the observed spectrum and a known peptide from the database. Using a simple
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model, the theoretical spectrum of peptide is calculated. A displacement value is added to
the m/z value of each peak in the spectrum. The correlation is then computed between the
observed spectrum and the theoretical spectrum with the displacement value included. The
peptide with the highest score is chosen as the estimated peptide (Xu and Ma, 2006).
A major concern of the database search and hybrid method is that they rely on the use
of a database of peptides. These methods cannot correctly identify the protein if it is not in
the database. Some limitations of de novo peptide sequencing are lack of accuracy and cer-
tainty of the chosen peptides, chemical noise, overly complex fragments, and incomplete b
and y ion sequences (Lubec and Afjehi-Sadat, 2007). We introduce a Bayesian model that
will aim to identify the correct peptide without depending on the database of peptides, but
instead using more generic prior information.
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CHAPTER 3
BASIC CONCEPTS OF FRAGMENTATION
The basic idea of any protein identification method is to match an observed spectrum to
a theoretical spectrum of the proposed peptide. It is extremely difficult to identify intact
proteins and so the proteins are broken into short peptides and examined separately. A pep-
tide is a sequence of amino acids, each of which is represented by one of 20 letters. Table
3.1 is a list of all 20 amino acids with their corresponding 3 letter and 1 letter codes. The
single letter code is used throughout the thesis to ease notation. The theoretical spectrum
of a peptide is a set of peaks with the location of each peak at the m/z value of each ion
type. There are spikes at each peak location and zeros everywhere else. The peptide is
broken into pairs of ions, most commonly b and y ions. It is the intensities of these ions
that are detected in the mass spectrometer. Figure 3.1 shows the theoretical spectrum for
the peptide QVMELLQ using just the b and y ions.
Table 3.1 The 20 amino acids with their corresponding 3 letter and 1 letter codes.
Amino Acid 3 Letter 1 Letter Amino Acid 3 Letter 1 Letter
Code Code Code Code
Alanine Ala A Leucine Leu L
Arginine Arg R Lysine Lys K
Asparagine Asn N Methionine Met M
Aspartic Acid Asp D Phenylalanine Phe F
Cysteine Cys C Proline Pro P
Glutamine Gln Q Serine Ser S
Glutamic Acid Glu E Threonine Thr T
Glycine Gly G Tryptophan Trp W
Histidine His H Tryosine Try Y
Isoleucine Ile I Valine Val V
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Figure 3.1 Theoretical spectrum for the peptide QVMELLQ using only b and y ions.
Here 1 represents the presence of an ion and 0 represents the absence of an ion. The b ion
is denoted by solid lines and the y ion is denoted by dashed lines.
To find the theoretical spectrum, one must first split the true peptide sequence into
all possible ion combinations. In practice, we use only the b and y ions, although there
are several other less common ions. A b ion is the start of the peptide that is terminated
by an amino acid with a free amine group (−NH2). An amine group is any group of
organic compounds of nitrogen. Therefore, we classify an ion as a b ion if the charge is
maintained on the N-terminus, where the N-terminus refers to the beginning of a peptide
that is terminated by an amino acid with a free amine group. In order for an ion to be
detected, the ion must have a charge of at least one. The y ion is the complement of the b
ion. Thus, it is the end of the peptide where the charge is maintained on the C-terminus,
where the C-terminus refers to the end of a peptide that is terminated by a free carboxyl
group (−COOH). A carboxyl group is an organic group containing a carbonyl bound to
a hydroxyl group where a carbonyl group is a group composed of a carbon atom double
bonded to an oxygen atom and a hydroxyl group is group composed of a hydrogen atom
covalently bonded to an oxygen atom (IUBMB, 1992, p. 48).
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b1 b2 b3 b4 b5 b6
Figure 3.2 Illustration of the fragmentation b ions. Each b ion is on the N-terminus. That
is, it is the beginning of the peptide. The first b ion is Q and the last b ion is QVMELL.
The splitting of the peptide is into all possible binary partitions.
After the b and y ions are found, the mass of each ion is determined. The mass for
any given ion is found by
∑k
i=1 m(pi) + δ` where k is the number of amino acids in the
ion sequence, pi is the amino acid in the i th position, m(pi) is the mass of the amino acid
in the i th position, ` denotes the type of ion such that ` ∈ {b, y}, and δ` is the offset for
ion type `. Table 3.3 shows a list of all twenty amino acids along with their corresponding
mass in Daltons (Da). In tandem mass spectrometry, the peptide fragmentation is deter-
mined by offsets that correspond to ion types. That is, the offsets match up to the peaks in
a given spectrum, and thus denote the different ion types created in the given mass spec-
trometer (Dančík et al., 1999). Dančík et al. (1999) develop an offset frequency function to
define ion type tendencies for particular mass spectrometers. A common problem was that
different types of mass spectrometers yield different spectra. Thus, Dančík et al. (1999)
developed an offset frequency function that does not depend on instrument type and allows
one to define the ion types produced by a given mass spectrometer. Table 3.2 lists different
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y1 y2 y3 y4 y5 y6
Figure 3.3 Illustration of the fragmentation y ions. Each y ion is on the C-terminus.
That is, it is the right-hand end of the peptide. The first y ion is Q and the last y ion is
VMELLQ. The splitting of the peptide is into all possible binary partitions.
ion types along with the terminus it can be detected from, the offset value, and how to
calculate the mass of the ion.
As an example, consider the peptide QVMELLQ. There are six b ions and six y
ions. The first b ion, Q, has a mass of 128.059 + 0.85 = 128.909 Da, and the first y
ion, Q, has a mass of 128.059 + 18.85 = 146.909 Da. Continuing with the splitting of
the peptide, one obtains the following additional b ions: QV , QVM , QVME, QVMEL,
and QVMELL with masses 227.977, 359.017, 488.060, 601.144, and 714.228 Daltons,
respectively. The fragmentation of each b ion can be found in Figure 3.2. Similarly, we
obtain the following additional y ions: LQ, LLQ, ELLQ, MELLQ, and VMELLQ
with masses 259.993, 373.077, 502.120, 633.160, and 732.228 Daltons respectively. The
fragmentation of each y ion can be found in Figure 3.3. Therefore, the theoretical spectrum
for the peptide QVMELLQ is the set of masses: 128.909, 227.977, 359.017, 488.060,
601.144, 714.2284, 732.228, 633.160, 502.120, 373.077, 259.993, and 146.909 Daltons.
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Table 3.2 Information about ion types. Here M denotes
∑k
i=1 m(pi).
Ion Terminus Offset Value Position
b N 0.85 (M + 0.85)
b-H2O N -17.05 (M - 17.05)
a N -27.15 (M - 27.15)
b-NH3 N -16.15 (M - 16.15)
b-H2O-H2O N -35.20 (M - 35.20)
b-H2O-NH3 N -34.20 (M - 34.20)
a-NH3 N -44.25 (M - 44.25)
a-H2O N -45.15 (M - 45.15)
y C 18.85 (M + 18.85)
y-H2O C 0.90 (M + 0.90)
y2 C 20.05 (M + 20.05)/2
y-NH3 C 1.90 (M + 1.90)
y2-H2O C 2.30 (M + 2.30)/2
y-H2O-NH3 C -16.10 (M - 16.10)
y-H2O-H2O C -17.15 (M - 17.15)
Table 3.3 The 20 amino acids with their corresponding masses in Daltons.
Amino Acid Mass Amino Acid Mass
A 71.0371 M 131.04
C 103.009 N 114.043
D 115.027 P 97.0528
E 129.043 Q 128.059
F 147.068 R 156.101
G 57.0215 S 87.032
H 137.059 T 101.048
I 113.084 V 99.0684
K 128.095 W 186.079
L 113.084 Y 163.063
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These positions are shown on the (m/z) axis in Figure 3.1.
It is important to find the total mass of the peptide because a mass spectrometer will also
measure the total mass of the peptide being analyzed. We can use this weight restriction
to eliminate peptides that do not have a total mass within a tolerance of the measured
mass. The total mass of the peptide is found by
∑K
i=1 m(pi) + mass of H2O, where the
mass of the water is molecule 18.010565 Da. Here K is the number of amino acids in the
peptide sequence. For data that are doubly charged, the total mass becomes
∑K
i=1 m(pi) +
mass ofH2O+H because of the second proton that is acquired. The mass of one hydrogen
molecule is 1.00794 Da. Thus the total mass for the peptide QVMELLQ is 860.456 Da




We propose a Bayesian model with the goal of identifying the true peptide based on the
observed spectrum. To identify this true peptide, a Markov chain Monte Carlo (MCMC)
algorithm is used to simulate candidate peptide sequences from the posterior distribution.
The motivation will be discussed in Section 4.2.
4.1 PRE-PROCESSING
Mass spectrometry data are quite noisy and thus the observed spectrum first needs to be
thresholded. In other words, peaks with intensity values below a threshold level will be
ignored, and our attention will be focused on the m/z values having intensities above
the threshold. A distinct threshold value for each integer m/z value, denoted by T =
(T1, T2, . . . , Tq?), is computed. Here q? denotes the total number of m/z values. Both a
constant threshold and a moving threshold are calculated. Then a weighted average of the
thresholds is used. For the constant threshold, the c th percentile of the observed intensity
values is computed and this computed c th percentile becomes a component of t, which is a
constant vector of the c th percentile with length q?. The value of c will typically be chosen
to be fairly high (such as 75) so that the only highest intensities are retained.
Consider a peptide whose intensity values range from 1 to 2500 Da with a total of 258
pairs of intensities and m/z values. Using the 75 th percentile, the constant threshold value
turns out to be 35.03 and therefore, each element of t would be 35.03. If one uses just a
constant threshold, then the data used in our method would be a set of m/z and intensity
values where the intensity values would be greater than or equal to 35.03.
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The mass spectrometer does not always capture all peaks at the beginning and the end
of the spectrum. Thus using only a constant threshold could remove peaks that are truly
signal peaks and not noise peaks. Therefore, we threshold using a combination of constant
and moving thresholds.
A moving threshold is then calculated as follows:
1. Consider any fixed m/z value x∗.
2. A subsection of the m/z values is selected using a window width of 50 Daltons on
either side of x∗.
3. The c th percentile of the observed intensity values within the window around x∗ is
found.
4. This is done for a fine grid ofm/z values, and each computed c th percentile becomes
a component of t′ = (t′1, t′2, . . . , t′q?).
Now consider the same peptide whose intensity values range from 1 to 2500 Da with
a total of 258 pairs of intensities and m/z values. Here each element of t′ will be the
75 th percentile of each observed instensity within a window of x∗. For this example, the
elements of t′ range from 14.25 to 124.81.
Now, using both the constant and moving thresholds, a weighted average is then found.
1. A sequence of weights, denoted as v, is computed having initial component 0.999
and with equally-spaced components decreasing linearly until the middle component
of 0.25 and then increasing until the last component of 0.999. This serves as the
weight vector for the constant threshold.
2. (1− v) is then the sequence of weights for the moving threshold.
3. v ◦ t and (1− v) ◦ t′ are computed and denoted ν1 and ν2, respectively, where v ◦ t
gives the elementwise product here.
20
4. The elementwise sum of ν1 and ν2 is found and each value becomes a component of
T , i.e. T = ν1 + ν2.
5. Each observed m/z value is matched up with the nearest corresponding threshold
value within T .
6. If the observed m/z value has a corresponding observed intensity value that is above
the threshold value in T , then the observed intensity value is retained. Otherwise,
the observed intensity value and corresponding observed m/z value is removed.
The data used in our method contain the retained intensity values and their corresponding
m/z values. Figures 4.1, 4.2, and 4.3 illustrate how thresholding reduces the noisy peaks
in the spectrum for different peptides. Figure (a) in each plot shows the full observed
spectrum before thresholding and Figure (b) in each plot shows the observed spectrum after
thresholding. Figure (a) in the Figures 4.1, 4.4, and 4.5 show the full observed spectrum
before thresholding for the same peptide while Figure (b) shows the observed spectrum
after thesholding using a different value for the c th percentile. One can see that the smaller
the value of c, the more peaks remain in the spectrum. As the value of c becomes larger, the
fewer peaks remain in the spectrum. Thus, the value of c is important and must be chosen
correctly so that it does not allow too many noise peaks or does not eliminate too many
signal peaks from the observed spectrum.
4.2 LIKELIHOOD
For our Bayesian model, we first specify a likelihood function, which gives a measure of
how well the observed spectrum and theoretical spectrum agree. If a candidate peptide’s
theoretical spectrum does not align well with the observed spectrum, an overall goodness of
fit measure is computed that will penalize the candidate peptide. However, if the theoretical
spectrum does align nicely with the observed spectrum, the overall goodness of fit measure
will reward the candidate peptide. Even after thresholding, we still expect there to be
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Figure 4.1 Figure (a) shows an observed spectrum before thresholding. Figure (b) shows
the observed spectrum after thresholding. The c th percentile was set to be 75% when
calculating the threshold.























Figure 4.2 Figure (a) shows an observed spectrum before thresholding. Figure (b) shows
the observed spectrum after thresholding. The c th percentile was set to be 75% when
calculating the threshold.
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Figure 4.3 Figure (a) shows an observed spectrum before thresholding. Figure (b) shows
the observed spectrum after thresholding. The c th percentile was set to be 75% when
calculating the threshold.



















Figure 4.4 Figure (a) shows an observed spectrum before thresholding. Figure (b) shows
the observed spectrum after thresholding. The c th percentile was set to be 50% when
calculating the threshold.
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Figure 4.5 Figure (a) shows an observed spectrum before thresholding. Figure (b) shows
the observed spectrum after thresholding. The c th percentile was set to be 90% when
calculating the threshold.
noise peaks in the data set and therefore, we incorporate another overall goodness of fit
measure that will penalize a candidate peptide when there are too many noise peaks near
the theoretical spectrum and reward a candidate peptide when there are not. We do know
that the mass spectrometer does not always capture every signal peak. Hence, we include
an indicator function in our likelihood function that signifies the presence or absence of a
peak.
We propose a likelihood function of the form
L(X|θ,η, κ1, κ2) ∝ κs1 exp(−κ1S1)κt−s2 exp(−κ2S2) (4.1)
where our parameter vector θ = (τ b1 , . . . , τ bp , λb1, . . . , λbp, τ
y




1, . . . , λ
y
p) and X
contains the observed pairs of m/z values and intensities for a particular spectrum and
η represents the string of amino acids for the candidate peptide. The other parameters are
explained below. The size of the likelihood function is driven by two overall goodness of





















|xj − τ ki | (4.3)
where k ∈ {b, y}, xj are the observed m/z values that have corresponding observed inten-
sity values above T , and τ bi and τ
y
i are the m/z values for the b and y ion of the candidate
peptide, respectively, for i = 1, . . . , p. Here, p represents the number of b ions (or, equiv-
alently, the number of y ions) and t represents the number of m/z values that have an
intensity above the threshold T . Also, κ1 and κ2 represent weights where s is the number
of b and y ions combined. Here λbi and λ
y
i ∈ {0, 1} are indicator functions that signify
whether the i th b or y ion has a corresponding observed peak, where i = 1, . . . , p. Here,
λbi = 1 denotes the presence of a b ion at position i and λ
b
i = 0 denotes the absence of a b
ion. Similarly, λyi = 1 denotes the presence of a y ion at position i and λ
y
i = 0 denotes the
absence of a y ion.
Here, S1 measures the sum of minimum absolute distances between the closest ob-
served m/z above a threshold and each m/z peak value of the candidate peak value, while
S2 measures the sum of minimum absolute distances between each observed m/z value
above a threshold and the closest candidate peak m/z values. That is, S1 measures the
closeness of the nearest observed peak to each candidate b ion or y ion, and S2 measures the
closeness of the nearest candidate peak to each observed peak. When all peaks for the can-
didate peptide are very close to observed peaks that are above the threshold, then exp (−S1)
is high. When all the observed peaks are close to candidate peaks, exp (−S2) will be high.
One can think of exp (−S1) and exp (−S2) in terms of sensitivity and specificity. Table 4.1
illustrates this analogy. Therefore, exp (−S1) is high when the false negative rate is low
and exp (−S2) is high when the false positive rate is low.
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Table 4.1 This table shows relationship between exp (−S1) and exp (−S2) and
sensitivity and specificity. Thus, when the true positive rate is high (exp (−S1) is high),
this corresponds to a high sensitivity rate. When the true negative rate is high (exp (−S2)
is high), this corresponds to a high specificity rate.
Candidate True Peptide Sequence
Peak No Peak
Observed Spectrum
Peak True Positive False Positive
No Peak False Negative True Negative
4.3 PRIORS
Huang et al. (2004) estimated the average bond cleavage abundance for each amino acid
pair for both the b and y ions for gas-phase dissociation spectra. Many studies involving
protein identification obtain gas-phase dissociation spectra. Collision-induced dissocia-
tion (CID) fragments the peptides even further: When an ion collides “with a gaseous
target, energy is redistributed among different vibrational degrees of freedom within the
ion” (Wysocki et al., 2006, p. 283). Further fragmentation leads to formation of charged
ions (Wysocki et al., 2006). There is limited knowledge about unimolecular dissociation
(Huang et al., 2004). Huang et al. (2004) shed light on some of the factors that affect uni-
molecular dissociation by exploring cleavage abundance for both b and y ions. A cleavage
occurs when the peptide bond fragments during collision induced dissociation. Therefore,
a cleavage pair is the b and y ion pair that are present in the peptide. For example, take the
peptideQVMELLQ. Recall from Chapter 3 thatQV is one of the six b ions of the peptide
QVMELLQ and the complement to that b ion is the y ion MELLQ. These complemen-
tary ions are a result of the cleavage between the amino acids V and M . This information
from Huang et al. (2004) will give us insight about when we expect to see cleavages in the
pairs of amino acid residues, and thus we use this information to develop prior information
about cleavage pair abundance for our Bayesian approach to identify the true peptide.
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Figure 4.6 A display of the geometric mean of average relative abundances of bond
cleavages of b and y ions for any particular amino acid pair using Figure 1 in Huang et al.
(2004). Note that this is a linear transformation of the scale used in Huang et al. (2004).
The linear transformation is of the form ρ = 0.49x+ 0.67. The y-axis is the the single
letter code of the amino acid on the N-terminal amino acid and the x-axis is the single
letter code of the amino acid on the C-terminal amino acid.
Cleavage Prior
The cleavage pair abundance prior is denoted π(λ|β,γ). For notational simplicity we write








P (λbi = λ
y
i = 1) = ρ
by
i × γi × βi
P (λbi = 1, λ
y
i = 0) = ρ
by
i × (1− γi)× βi
P (λbi = 0, λ
y
i = 1) = ρ
by
i × γi × (1− βi)
P (λbi = λ
y




i × (1− γi)× (1− βi)]
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where λ = (λb,λy) = (λb1, . . . , λbp, λ
y




i is the geometric mean of the average
relative abundance of bond cleavages of b and y ions for a particular amino acid pair for i =
1, . . . , p derived from Huang et al. (2004), γi is the probability of the presence of a y ion,
and βi is the probability of the presence of a b ion. Note that we use a linear transformation
of the probability ρ = 0.49x + 0.67, as explained below. Here, p represents the number
of cleavage pairs. Note that the λbi ’s are modeled as having random marginal Bernoulli
distributions with probabilities ρbyi βi and the λ
y
i s are modeled as having random marginal
Bernoulli distributions with probabilities ρbyi γi, and λbi , λ
y
i are all mutually independent for
i = 1, . . . , p. The proof of the λbi ’s and λ
y
i ’s having a marginal Bernoulli distribution is
shown below. Let P (λbi = xb, λ
y
i = xy).
P (λbi = 1) =
∑
x
P (λbi = 1, λ
y
i = x)




P (λbi = 0) =
∑
x
P (λbi = 0, λ
y
i = x)




i (1− γi)(1− βi)
= ρbyi (1− βi) + 1− ρ
by
i
= 1− ρbyi βi
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The derivation for the λyi ’s can shown below:
P (λyi = 1) =
∑
x
P (λbi = x, λ
y
i = 1)




P (λyi = 0) =
∑
x
P (λbi = x, λ
y
i = 0)




i (1− γi)(1− βi)
= ρbyi (1− γi) + 1− ρ
by
i
= 1− ρbyi γi.
As an example, consider the peptide QVMELLQ. From Chapter 3, we know that
there are six b and y ions. Therefore, we will require λb and λy each to have six elements.
Suppose we set the probabilities for the presence of each ion to be contained in vectors
β = [0.05, 0.9, 0.9, 0.9, 0.9, 0.75] and γ = [0.1, 0.9, 0.9, 0.9, 0.9, 0.75]. The probabilities
can be different for each element, as illustrated. These types of values for the β and γ
vectors are motivated in Chapter 7. For example, suppose we have λb = [0, 1, 1, 1, 1, 0]
and λy = [0, 1, 1, 1, 0, 1]. The first cleavage pair for the peptide QVMELLQ is QV . Con-
tinuing with the splitting of the peptide, one obtains the following cleavage pairs: VM ,
ME, EL, LL, and LQ. Using Figure 4.6, we obtain the vector of geometric mean of
the average relative abundance of bond cleavages of b and y, ρby = (ρby1 , . . . , ρby6 ) =
(0.802, 0.835, 0.769, 0.785, 0.818, 0.785). Figure 4.6 shows the geometric mean of the av-
erage bond cleavage abundance for all cleavage pairs of the b and y ions using Figure 1 in
Huang et al. (2004). Note that probabilities for a particular amino acid cleavage pair that
are too close to zero may force the algorithm to exclude reasonable peptides. In order for
our prior to be more inclusive, we use a linear transformation of the scale used in Huang
et al. (2004). The linear transformation is of the form ρ = 0.49x + 0.67. Our rescaled
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distribution has probabilities that range from 0.67 to 1.00. The cleavage pair abundance
prior probability for the example above is given by
P (λb1 = λ
y
1 = 0) = 1− 0.802 + [0.802× (1− 0.1)× (1− 0.05)] = 0.884
P (λb2 = 1, λ
y
2 = 1) = 0.835× 0.9× 0.9 = 0.676
P (λb3 = 1, λ
y
3 = 1) = 0.769× 0.9× 0.9 = 0.623
P (λb4 = 1, λ
y
4 = 1) = 0.785× 0.9× 0.9 = 0.636
P (λb5 = 1, λ
y
5 = 0) = 0.818× (1− 0.9)× 0.9 = 0.074
P (λb6 = 0, λ
y




P (λbi , λ
y
i ) = 0.0029, and
loge π(λ) = −5.84.
As a matter of notation, note that our parameter vector θ (= θγ, β) depends on the
values of γ and β, but our notation will suppress this dependency since γ and β will remain
fixed throughout the algorithm.
Sequence Prior
We now want to specify a prior distribution for a particular sequence (or string) of amino
acids in a peptide. The probability of any particular amino acid sequence is represented by
the string prior, π(η), which quantifies the probability of a sequence of amino acids appear-
ing consecutively in a peptide sequence. For each amino acid pair in the candidate peptide
under consideration, we count how often the pair occurs in the set of known peptides from
the same species. Then we find the empirical probability of each amino acid pair using our
large database of peptides. Note that one could use other databases that do not contain the
current peptide to calculate the empirical probability. The string prior is defined as
π(η) =
√
π(ηF )× π(ηR), (4.5)
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where π(ηF ) is the joint probability of any particular amino acid sequence calculated from
left to right while π(ηR) is the joint probability of any particular amino acid sequence
calculated in the reverse direction. Note that this is the geometric mean of π(ηF ) and
π(ηR). Here η is the ordered sequence of the amino acids in the current peptide under
consideration, and π(η) is a probability for this particular sequence. Denote a generic
peptide sequence by A1A2 · · ·Am−1, where m − 1 is the number of amino acids in the
peptide sequence, A0 denotes the beginning of the sequence, andAm denotes the end of the
sequence. For example, consider the peptide TGMSNV SK. For this candidate peptide
having 8 amino acids, m = 9. π(ηF ) is calculated by
π(ηF ) = P (A1 = a1)×
m−1∏
i=1
P (Ai+1 = ai+1|Ai = ai) (4.6)
with P (A1 = a1) = p1, P [(Ai, Ai+1) = (ai, ai+1)] = pi,i+1, and therefore P (Ai+1 =
ai+1|Ai = ai) =
pi,i+1∑
j P [(Ai, Ai+1 = (ai, j)]
for j ∈ {A,C, . . . , Y, } where ai represents
the amino acid in the i th position in the peptide sequence and am = signifies the termi-
nation of a sequence. In a similar manner, π(ηR) is computed by
π(ηR) = P (Am−1 = am−1)×
m−2∏
i=0
P (Ai = ai|Ai+1 = ai+1) (4.7)
with P (Am−1 = am−1) = pm−1, P (Ai = ai|Ai+1 = ai+1) =
pi,i+1∑
j P [(Ai, Ai+1 = (j, ai+1)]
for j ∈ {A,C, . . . , Y, } where a0 = signifies the beginning of a peptide sequence.
We illustrate the calculation of this type of prior probability using the peptide TGMSNV SK
from the salmonella typhimurium species. First note that the empirical probability that the
initial amino acid in a peptide is T is 0.0614. The empirical probability that a random
ordered pair of amino acids is TG is 0.0067, and so on. Figure 4.7 shows the joint empir-
ical probabilities for all pairs of amino acids. The probability of the particular amino acid
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sequence for the peptide TGMSNV SK in the forward direction, π(ηF ), is found by:
P (A1 = T ) = 0.0614
P (A2 = G|A1 = T ) =
P [(A1, A2) = (T,G)]
P [(A1, A2) = (T,A)] + · · ·+ P [(A1, A2) = (T, )]
= p1,2
P [(A1, A2) = (T,A)] + · · ·+ P [(A1, A2) = (T, )]
= 0.00670.0500 + · · ·+ 0.0019 = 0.0992
...
P (A8 = K|A7 = S) =
0.0019
0.0654 = 0.0295




π(ηF ) = P (A1 = T )×
∏9
i=1 P (Ai+1 = ai+1|Ai = ai) = 4.26× 10−11 and
loge π(ηF ) = −23.88.
The probability for the reverse direction, π(ηR), is calculated similarly and is shown below:
P (A8 = K) = 0.5146
P (A7 = S|A8 = K) =
P [(A7, A8) = (S,K)]
P [(A7, A8) = (A,K)] + · · ·+ P [(A7, A8) = ( , K)]
= p1,2
P [(A7, A8) = (A,K)] + · · ·+ P [(A7, A8) = ( , K)]
= 0.00190.0059 + · · ·+ 0.0107 = 0.0130
...
P (A1 = T |A2 = G) =
0.0067
0.1229 = 0.0545




π(ηR) = P (A1 = T )×
∏8
i=0 P (Ai = ai|Ai+1 = ai+1) = 1.31× 10−12 and
loge π(ηR) = −27.36.
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Therefore, we have π(η) =
√
4.26× 10−11 × 1.31× 10−12 = 7.47×10−12 and so loge π(η) =
−25.62.





























Figure 4.7 The joint empirical probabilities for all pairs of amino acids. For ease of
identifying the different joint empirical probabilities, the figure is shown on the log-scale.
The y-axis is the single letter code of the amino acid for the first amino acid in the pair
and the x-axis is the single letter code of the amino acid for the second amino acid in the
pair. The darker the square, the less probable the pair.
Prior for κ1, κ2
The concentration parameters, κ1 and κ2, are assumed to have independent Gamma(a1, b1)




Using Bayes’ Theorem, the posterior density can be written as
π(η,λ, κ1, κ2|X) ∝ L(X|λ, τ ,η, κ1, κ2)× π(λ)× π(η, τ )× π(κ1, κ2) (4.8)
= L(X|θ,η, κ1, κ2)× π(λ)× π(η)× π(κ1, κ2), (4.9)
where λ, η, and κ1, κ2 are assumed independent. Note that the set of m/z locations given
by τ = (τ b1 , . . . , τ bp , τ
y
1 , . . . , τ
y
p )T are determined by the sequence η, and so P (τ |η) = 1.
Note that this posterior density is only known up to a constant and the actual form of
the posterior density is complicated. Therefore, to obtain the posterior probabilities we
must use MCMC simulation. Our Bayesian method incorporates prior information about
the chance of seeing particular cleavage pairs, and also quantifies the prior probability
of any particular specific amino acid sequence. We use this posterior density to estimate
the true peptide, with candidate peptides having high posteriors being judged more likely
to be the true peptide. Our point estimate of the true peptide is the posterior mode, that
is, the candidate peptide (among those visited by the search algorithm) with the highest
posterior probability, and the posterior distribution variance provides information about
the uncertainty of the estimate.
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CHAPTER 5
A MARKOV CHAIN MONTE CARLO ALGORITHM
5.1 MARKOV CHAIN MONTE CARLO
There are various circumstances in which we wish to sample from a particular distribu-
tion but it can be extremely difficult especially when the normalizing constant is unknown.
Markov chain Monte Carlo simulations allow one to sample from these complex distribu-
tions. A Markov chain is a sequence of random variables {Xn;n ≥ 0} with an invariant
distribution π that is constructed from a transition kernel. A random process is consid-
ered to be a Markov process if the transition probabilities between the different values
in the state space depend only on the current state. A transition kernel is a function P
defined by P (Xn, A) = P{Xn+1 ∈ A|X0, . . . , Xn} such that for all measurable sets A,
π(A) =
∫
π(dx)P (x,A). A Markov chain is considered to be irreducible if for an initial
state there is a positive probability that it will visit every state in the state space. That
is, one can move from any state to any other state. A Markov chain with a finite number
of values is considered to be aperiodic if the greatest common divisor of return times to
any particular state is 1 (Tierney, 1994; Robert and Casella, 1999; Andrieu et al., 2003;
Sorensen and Gianola, 2002).
Markov chain Monte Carlo (MCMC) refers to methods for sampling from an invariant
distribution based upon the construction of a Markov chain. The Metropolis-Hastings algo-
rithm (Metropolis et al., 1953; Hastings, 1970; Andrieu et al., 2003; Sorensen and Gianola,
2002) is a type of MCMC method that obtains a sequence of random samples with a com-
plex invariant distribution. The Metropolis-Hastings algorithm begins with a target density
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π. Then a conditional density q(y|x) is chosen and the algorithm produces a Markov chain
{X(t)} through a Markov transition. Here q is called the proposal distribution. The transi-
tion is described as follows for a given x(t):
















Because the Hastings ratio only depends on the ratio of target densities, the complicated
normalizing constant need not be known.
The Gibbs Sampler (Geman and Geman, 1984; Gelfand and Smith, 1990) is a special
case of the Metropolis-Hastings where the random value is always accepted and only uni-
variate full conditional distributions are considered. A univariate distribution implies that
all the random variables have fixed values but one. One then simulates n random variables
sequentially from the n univariate conditionals in order to produce a sample from the full
joint distribution (Robert and Casella, 1999).
5.2 INITIALIZATION
We first need to find a starting peptide for the MCMC algorithm. We will only consider
candidates with the overall correct mass (within a tolerance) when generating an initial
candidate. One option is to use an initial iterative sub-algorithm to obtain a starting peptide.
Note the actual mass of the true peptide is available to us from the mass spectrometry data,
and so we can dramatically reduce the parameter space by searching for peptides with a
mass within a specific tolerance of the actual mass, which we take as ± 0.5 Da. Here is the
algorithm for obtaining the random starting point.
INITIALIZATION ALGORITHM
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1. The weight of the true peptide is given.
2. A random sample of either one, two, or three amino acids is selected as the initial
guess, ηcurr, for the starting peptide and the mass of the resulting peptide is found.
3. Let ∆ be the weight of the true peptide and ∆curr be the weight of the current peptide.
Then r1 = |∆−∆curr| is calculated.
4. If r1 is less than a tolerance of 0.5 Daltons, then ηcurr becomes the starting peptide.
However, if r1 ≥ 0.5, then we randomly add or remove either one, two, or three
amino acids creating a new peptide, ηnew.
5. For each addition or removal, the weight ∆new of the resulting new peptide is found
and r2 is calculated where
r2 = exp (− ( |∆−∆new| − |∆−∆curr|)) . (5.1)
6. r2 is then compared to U ∼ U(0, 1).
7. If r2 > U , then ηnew becomes ηcurr, otherwise ηcurr is unchanged.
8. Go to 3.
This algorithm continues until a peptide is found having a weight within 0.5 Da of the true
peptide’s weight. To illustrate this algorithm, consider the true peptide AQLQEIQTK
having a total mass of 1058.59 Da. After running the algorithm with that total mass, the
random starting peptide is GPLHAPWGSH , having a total mass of 1058.52 Da, which
is within 0.5 Da of the total mass of the true peptide.
While using the method above will reduce the space of initial peptides, it may still yield
a starting peptide far from the truth if the peptide sequence is long, which could result in
our method taking a long time to search for the true peptide.
Another option for finding a starting peptide is to use the results from PepNovo. Pep-
Novo yields a list of the top 2000 best estimated peptides for the true peptide. We can use
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a peptide from this list as our starting peptide. We still ensure the starting peptide will have
the correct total mass within a tolerance. Here we provide an example of how we use a start-
ing peptide from the PepNovo results. Consider the same true peptide AQLQEIQTK.
We then choose a random protein from the list of the top 2000 estimated peptides from
PepNovo. Some of the estimated peptides may not have the correct total mass within a
tolerance, and so we must choose a peptide that satisfies our weight constraint. Therefore,
a starting peptide could be, for example, KALQNQAQTQ.
5.3 POSTERIOR SIMULATION
Once the starting peptide is generated, the log likelihood of that peptide is calculated using
the likelihood defined above. Let us call the current peptide ηcurr (initially this will be the
starting peptide). The β and γ vectors are pre-determined at the beginning of the algorithm
and are constant throughout the algorithm. Before the algorithm begins, a vector λcurr is
generated using the β and γ vectors.
MARKOV CHAIN MONTE CARLO ALGORITHM
1. A new peptide is created by randomly replacing one, two, or three amino acids of the
current peptide with one, two, or three amino acids.
2. Generate κ1 from its full conditional distribution, a Gamma distribution with the
shape parameter α1 = a1+s and scale parameter β1 = S1+b1. Similarly, generate κ2
from its full conditional distribution, a Gamma distribution with the shape parameter
α2 = a2 +(t−s) and scale parameter β2 = S2 + b2. Here, a1, b1, a2, and b2 are some
constants chosen as parameters of the priors for κ1 and κ2. Note that the values of S1
and S2 are based on the current peptide.
3. The log likelihoods of the current peptide and new peptide are then found and de-
noted as `curr and `new, respectively.
4. Generate λnew using β and γ.
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5. Calculate π(λnew), π(λcurr), π(ηnew), and π(ηcurr) up to a constant.
6. The posterior probability is computed for both the new and current peptide. Denote
these as ζ1 and ζ2, respectively.
7. The proposal densities q(λcurr|λnew), q(λnew|λcurr), q(ηcurr|ηnew), and q(ηnew|ηcurr)
are calculated.










new peptide becomes the current peptide, and λnew becomes λcurr. Otherwise, both
the current peptide and λcurr remain unchanged.
9. Go to 1.
When exploring large state spaces stochastically, it is important that the algorithm be
irreducible. That is, we must ensure it may visit every potential state with positive prob-
ability (Tierney, 1994). In order to ensure irreducibility, every 1000 steps we generate an
entirely new peptide that is independent of the current state. Note that any sequence with
the correct mass has positive probability of being generated in this step (Tierney, 1994).
Steps 1 - 9 are repeated for a specific number of iterations (e.g., 25, 000). The peptide
with the largest posterior density is selected as the true peptide, and we retain all generated
peptides along with their approximate posterior probabilities (up to a constant).
We argue that our state space is finite, because for any given spectrum, the peptide can-
not be arbitrarily long. Stochastic search algorithms with finite state spaces typically sat-
isfy certain theoretical properties more readily than those with an infinite number of states
(Tierney, 1994). A mass spectrometer will always accurately measure the total weight of
the true peptide and thus, there is a maximum number of residues that will produce a pep-
tide of that weight. The amino acidG has the smallest mass of 57.0215. Therefore, a string
of all G’s would be the longest peptide for a required mass.
Trace plots of the log posterior and parameters will be used to monitor convergence of
the algorithm. Trace plots are plots of specific sampled values versus a simulation index.
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Here our simulation index is the number of iterations. This plot allows one to see whether
the chain has converged to its stationary distribution. Another use of a trace plot is to see
whether the chain is mixing well. A chain that mixes well will cross its posterior space
quickly (SAS Institute Inc., 2009).
To calculate the first proposal densities we need to calculate q(λcurr|λnew) and q(λnew|λcurr).
Note that q(λcurr|λnew) = q(λcurr) and q(λnew|λcurr) = q(λnew) since the new λ is
generated independently of the current λ. Recall that λ follows a Bernoulli distribu-
tion. Suppose Λ is a multinomial random variable and λ is a particular vector. Sup-
pose we set β = (0.05, 0.99, 0.99) and γ = (0.10, 0.99, 0.99) and suppose we have
λcurr = (0, 1, 1, 0, 1, 1) and λnew = (0, 0, 1, 1, 0, 1). We would calculate the proposal
densities as follows:
q(λcurr|λnew) = q(λcurr) = P (Λcurr = λcurr)
= (0.95)× (0.99)× (0.99)× (0.90)× (0.99)× (0.99)
= 0.82
and
q(λnew|λcurr) = q(λnew) = P (Λnew = λnew)
= (0.95)× (0.01)× (0.99)× (0.10)× (0.01)× (0.99)
= 9.3× 10−6.
To calculate the second set of proposal densities we need to calculate q(ηcurr|ηnew)
and q(ηnew|ηcurr). Recall from step 1 of the MCMC algorithm, we are always replacing
either one, two, or three amino acids of the current peptide with either one, two, or three
amino acids. Hence we know that there is a 1/3 chance that we will choose either one, two,
or three amino acids to be replaced. If only one animo acid is chosen to be replaced, then
there is a 1/n chance that any particular amino acid will be chosen. Here n represents the
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total number of amino acids in the peptide sequence. If a pair of amino acids is chosen to
be replaced, then there is a 1/(n− 1) chance that a consecutive pair of amino acids will be
chosen. If three consecutive animo acids are chosen to be replaced, then there is a 1/(n−2)
chance that any particular triplet of consecutive amino acids will be chosen.
Also, note that the current and new peptide must have a total mass that is within a toler-
ance of the total mass of the true peptide. After the number of amino acids to be replaced is
fixed, a list of single, pairs, and/or triplets of amino acids is selected that each have a mass
within a tolerance of the mass of the amino acid(s) that is to be replaced. Therefore, the
probability that a particular single, pair, or triplet is chosen is 1/m where m is the number
of singles, pairs, and/or triplets in the list of amino acids that satisfy the weight tolerance.
If a pair or triplet is selected from the list, then we must consider all permutations of the
pair or triplet. For example, if the pair AK is selected from the list, we then randomly
select whether AK orKA is chosen. The probability for choosing a particular permutation
of a pair of amino acids is 1/2. The probability for choosing a particular permutation of
a triplet of amino acids is 1/q where q is the number of permutations of the three amino
acids. Since there are no permutations for a single amino acid, the probability is 1.
To illustrate the calculation of the proposal probabilities, let us look at an example.
Consider the current peptide to be TGMSNV SK and the new peptide to be TGMSNWK
with a tolerance level set to be 0.5. In order for the current peptide to be replaced by the
new peptide, the pair of amino acids V S needs to be replaced with the single amino acid
W . There is a 1/3 probability that a set of two amino acids is chosen to be replaced.
Since two amino acids are chosen to be replaced, the probability we choose the pair of
amino acids V S is 1/(8 − 1) = 1/7. The mass of V S is 186.1 and thus, we can only
replace the pair of amino acids with either one, two, or three amino acids that have a mass
within 186.1 ± the tolerance. Given that the tolerance is 0.5, we can only replace V S
with AD, EG, W , and SV . Therefore, the probability that W is selected is 1/4. Thus,
q(ηnew|ηcurr) = (1/3) × (1/7) × (1/4) × 1 = 0.012. Now, in order for the new peptide
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to be replaced by the current peptide, the amino acid W needs to be replaced with the
pair of amino acids V S. There is a 1/3 probability that one amino acid is chosen to be
replaced. Since one amino acid is chosen to be replaced, the probability we choose the
amino acid W is 1/7. The mass of W is 186.079 and thus, we can only replace the single
amino acid with either one, two, or three amino acids that have a mass within 186.079 ±
tolerance. Given that the tolerance is 0.5, we can only replace W with AD, EG, W , and
SV . Therefore, the probability that SV is selected is 1/4. Now we need to look at the
permutations of SV , which are SV and V S. The probability that V S is chosen is 1/2.




In this chapter, we simulate data based on our likelihood in order to get a better under-
standing of the tuning parameters, with the goal of recovering the theoretical spectrum
more often. One approach could be to generate a full spectrum with intensities at each
m/z location. Then one could pick out the m/z values that are above our threshold. Since
our algorithm uses only the m/z values that have intensities above a threshold, we will
instead generate a spectrum with signal and noise peaks that are already assumed to be
above a threshold. For a given peptide, we will know the locations of the true peaks. Let us
denote the true set of peak locations as τ = (τ1, . . . , τs), where s represents the total num-
ber of true peaks. Each true peak will then generate a signal peak and a random number
of noise peaks that are above the threshold. Here we look at two different noise structures,
one using the Laplace distribution and the other using a Poisson process.
6.1 LAPLACE NOISE STRUCTURE
We first employ the Laplace distribution to simulate noise peaks (Damsleth and El-Shaarawi,
1989; Kemp, 2003). Using the Laplace distribution ensures that we have a generative
model. A generative model randomly generates observable data by fixing a joint proba-
bility distribution over observation sequences. The basic idea of a generative model is to
model the data directly or aid in composing a conditional probability function, which is
formed through Bayes’ rule (Singla and Domingos, 2005). A generative model allows us
to generate spectra using our model that is defined in Chapter 4.
Mass spectrometers do not always capture peaks that appear at the beginning or end
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of the spectrum, causing the rate of noise peaks per signal peak to vary over an observed
spectrum. Therefore, before we generate a spectrum, we first split the observed spectrum
into three sections. Each section will contain a number of signal peaks, determined to
be a percentage of the total signal peaks. Then for each signal peak in each section, a
random number of noise peaks will be generated. To explain how to find the number
of signal peaks for each section, consider a peptide with s = 20 true peaks. The first
section will contain s1 = 20 × 0.1 = 2 signal peaks and the third section will contain
s3 = 20×0.1 = 2 signal. Thus the middle section will contain s2 = 20−2−2 = 16 signal
peaks. The proportions of 0.1 for each boundary section were chosen based upon extensive
numerical experimentation. For each section of the spectrum, we use a discrete uniform
with parameters a = 0 and b to determine the number of noise peaks per signal peaks to be
generated. The values of b depend upon the section of the spectrum. Lower values of b will
be chosen for the beginning and ending sections and a higher value of b will be chosen for
the middle section. Note that increasing b for each section will cause our data to become
noisier. For the first section, the value of b, denoted as b1, will be b1 = 3. For the middle
and third section the value of b will be b2 = 10 and b3 = 5, respectively. These values work
well after many analyses and tend to generate a moderate number of noise peaks.
We then simulate from a Laplace distribution to generate the locations of both the sig-
nal peak and noise peaks with fixed parameters κ1 and κ2. Figure 6.1 shows the plot of
generated signal peaks versus the true signal peaks (theoretical spectrum) for a given pep-
tide using different values of κ1. This illustrates how the choice of κ1 affects the location of
the generated signal peaks. The choice of κ1 for Figure 6.1 (a) is κ1 = 50, κ1 = 1000 for
Figure 6.1 (b), and κ1 = 0.05 for Figure 6.1 (c). Increasing κ1 does not have much effect
on the location of the generated signal peaks. However, upon decreasing κ1, the location of
the generated signal peaks are shifted from their location on the theoretical spectrum. To
illustrate how the choice of κ2 affects the location of the generated noise peaks, consider
the peptide TGMSNV SK. Figure 6.2 shows the plot of a generated spectrum versus the
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observed spectrum corresponding to the peptide TGMSNV SK and theoretical spectrum
for a given peptide using different values of κ2. This shows how the choice of κ2 affects
the location of the generated noise peaks. The choice of κ2 for Figure 6.2 (a) is κ2 = 0.10,
κ2 = 1.0 for Figure 6.2 (b), and κ2 = 0.01 for Figure 6.2 (c). Increasing κ2 causes the
location of the generated noise peaks to be tightly centered on the signal peaks. Decreasing
the value of κ2 causes the location of the generated noise peaks to spread out far from the
signal peaks.


























Figure 6.1 Simulated signal peaks plotted against the theoretical spectrum. The
simulated signal peaks are plotted above the zero axis. The theoretical spectrum is plotted
with the dashed lines below the zero axis. Values for κ1: (a) κ1 = 50, (b) κ1 = 1000, (c)
κ1 = 0.05.
The steps to generate a spectrum with Laplace noise structrue is as follows:
1. Determine the total number of true peaks, s, and compute τ by finding the b and y
ions, based on the given peptide.
2. Simulate signal peaks from a density f(xi) ∝ e−κ1|xi−τi| for i = 1, . . . , s.
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Figure 6.2 Simulated spectrum plotted against the observed spectrum and theoretical
spectrum. The simulated spectrum is plotted above the zero axis. The observed spectrum
is plotted with the solid lines below the zero axis and the theoretical spectrum is plotted
with the dashed lines below the zero axis. Values for κ2: (a) κ2 = 0.10, (b) κ2 = 1.0, (c)
κ1 = 0.01.
3. Use an indicator function λi with probability function P (λ) =
∏p
i=1 P (λbi , λ
y
i ),
where p = s − 1 is the total number of b ions (or, equivalently, the number of y
ions) to determine the presence or absence of each signal peak. P (λ) was given in
Section 4.3.
4. For each of the three sections in the spectrum, the number of noise peaks for each
signal peak in the section is generated using a discrete uniform.
5. Simulate noise peaks from a density f(xj) ∝ e−κ2|xj−τi|, where t represents the total
number of peaks for j = s+ 1, . . . , t.
The likelihood for the generated set of peaks is of the form
L ∝ κ1e−κ1
∑s
i=1 λi |xi−τi|κt−s2 e
−κ2
∑t
j=1 |xj−τj |. (6.1)
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Note the similarity of this expression with the previous likelihood in Equation 4.1 dis-
cussed Section 4.2, although it is not exactly the same. The first component in the likeli-
hood defined in Section 4.2 sums over the minimum absolute distances between the closest
observed peak to a candidate peak and the second component sums over the minimum
absolute distance between the nearest candidate peak to each observed peak. In Equation
6.1, the first component just sums over the absolute distances between the closest observed
peak to a candidate peak and the second component sums over the absolute distance be-
tween the nearest candidate peak to each observed peak. In the following simulations, we
use the previous likelihood in Equation 4.1, not Equation 6.1, for inference.
Example 6.1
Before simulating the spectrum, we must specify the parameters. We set κ1 and κ2 to be
50 and 0.10, respectively. For the indicator function λ, we set the first elements of β and
γ to be pb1 = 0.05 and py1 = 0.10. We set these probabilities to be low because the mass
spectrometer rarely captures the first b ion and first y ion and thus we want to ensure that
our simulated data represent the observed spectrum well. We set all other pbi and pyi to
equal 0.80 for i = 2, . . . , p.
We first consider a peptide with a short amino acid sequence. Consider the peptide
TGMSNV SK whose observed spectrum contains m/z values that range from 123 to 749
Da. The total number of true peaks is s = 14 and so s1 = 1, s2 = 12, and s3 = 1 using
boundary section proportions 0.1.
For each example shown (Examples 6.1, 6.2, 6.3, 6.4), a table of the top estimated
peptides is given along with their corresponding log posterior value. The breakdown of the
log posterior is also given to see which part of the model is most heavily influencing the log
posterior and to see why the true peptide is not estimated to the best (if that is the case). The
top estimated candidates are chosen as a percentage of unique candidate peptides accepted
by the algorithm. To illustrate how the top estimated candidates are chosen, consider that if
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the algorithm has 100 unique peptides that were accepted by the algorithm, then there will
be 100× 0.10 = 10 peptides (with the largest log posteriors) selected as the top estimated
peptides.
Figure 6.3 shows the plot of the simulated data versus the observed spectrum and the-
oretical spectrum. The simulated spectrum is plotted above the zero axis. The observed
spectrum is below the zero axis with solid lines and the theoretical spectrum is plotted
below the zero axis with dashed lines. One can see the simulated spectrum mimics the ob-
served spectrum reasonably well. After the spectrum is generated, our method described in








Figure 6.3 Simulated spectrum plotted against the observed spectrum and theoretical
spectrum when using the Laplace noise structure. The simulated spectrum is plotted
above the zero axis. The observed spectrum is below the zero axis with solid lines and the
theoretical spectrum is plotted below the zero axis with dashed lines.
Chapter 4 is then applied to the simulated spectrum. The starting peptide isGTMSGRSQ,
which was obtained from the results from PepNovo when applied to the real data. The al-
gorithm was run for 10000 iterations and the best estimated peptide for the true peptide is
TGMSGGV SK with a log posterior density of 28.18 (up to a constant). Table 6.1 shows
the top estimated peptides for the TGMSNV SK example using the simulated spectrum
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Table 6.1 The top estimated peptides from the MCMC algorithm along with their
corresponding log posterior densities, log likelihoood, log cleavage prior, log sequence
prior, log κ1 prior, and log κ2 prior for the peptide TGMSNV SK when using a
simulated spectrum.
Peptide Log Posterior Log Likelihood Log Cleavage Log Sequence Log κ1 Log κ2
Densities Prior Prior Prior Prior
TGMSGGVSK 28.18 58.57 -7.11 -28.31 5.41 -0.37
TGMSGGEGK 28.06 59.21 -9.14 -27.11 5.41 -0.30
TGMSNVSK 18.95 45.25 -5.60 -25.62 5.34 -0.41
TSTSNVSK 15.43 43.82 -7.97 -25.39 5.47 -0.50
SAMSNVSK 13.87 41.49 -6.85 -25.66 5.38 -0.50
TGFGKVSK 11.74 43.12 -8.82 -27.65 5.46 -0.37
SDSSNVSK 7.61 34.67 -7.33 -23.84 4.47 -0.37
along with their corresponding estimated log posterior densities with the breakdown of the
log posterior. The log likelihood and log priors are also given. We see that the true peptide
(highlighted in bold) is among the top estimated peptides. Here it is the third best peptide.
To ensure our algorithm is performing accurately, we simulate a spectrum with minimal
noise. To decrease the number of noise peaks, we set the values of b for each section of
the spectrum to be b1 = b2 = b3 = 2. We also generate a spectrum with substantial noise
by increasing the values of b for each section to b1 = b2 = b3 = 10. Our method was
then applied to both generated spectra. For both examples the algorithm was run for 10000
iterations with a starting peptide of GTMSGRSQ, which was obtained from the results
from PepNovo.
Figure 6.4 shows the plot of the simulated spectrum with minimal noise plotted against
the observed spectrum and theoretical spectrum. The best estimated peptide for the true
peptide when using minimal noise is TGMSNV SK with a log posterior density of 12.50
(up to a constant). Table 6.2 shows the top estimated peptides for the TGMSNV SK ex-
ample using the simulated spectrum with minimal noise along with their corresponding
estimated log posterior densities with the breakdown of the log posterior. The log likeli-
hood and log priors are also given. We see that the true peptide (highlighted in bold) is the
top estimated peptide, which ensures our method is performing substantially well.
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Figure 6.4 Simulated spectrum with minimal noise plotted against the observed and
theoretical spectra when using the Laplace noise structure. The simulated spectrum is
plotted above the zero axis. The observed spectrum is below the zero axis with solid lines
and the theoretical spectrum is plotted below the zero axis with dashed lines.
Table 6.2 The top estimated peptides from the MCMC algorithm along with their
corresponding log posterior densities, log likelihoood, log cleavage prior, log sequence
prior, and log κ1 and log κ2 prior for the peptide TGMSNV SK when using a simulated
spectrum with minimal noise.
Peptide Log Posterior Log Likelihood Log Cleavage Log Sequence Log κ1 Log κ2
Densities Prior Prior Prior Prior
TGMSNVSK 12.50 45.39 -9.88 -27.45 5.22 -0.78
TGMSAAASK 10.76 41.15 -7.26 -27.09 4.87 -0.90
TGMGTAGTK 6.04 41.02 -9.95 -27.41 3.01 -0.64
TGMGTAASK 5.32 39.66 -9.23 -27.45 2.98 -0.60
TGMSAATGK 3.69 37.03 -8.51 -26.53 2.59 -0.88
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Figure 6.5 shows the plot of the simulated spectrum with substantial noise plotted
against the observed spectrum and theoretical spectrum. The best estimated peptide for








Figure 6.5 Simulated spectrum with substantial noise plotted against the observed
spectrum and theoretical spectrum when using the Laplace noise structure. The simulated
spectrum is plotted above the zero axis. The observed spectrum is below the zero axis with
solid lines and the theoretical spectrum is plotted below the zero axis with dashed lines.
the true peptide when using substantial noise is TGMSAAASK with a log posterior
density of 40.36 (up to a constant). Table 6.3 shows the top estimated peptides for the
TGMSNV SK example using the simulated spectrum with substantial noise along with
their corresponding estimated log posterior densities with the breakdown of the log pos-
terior. The log likelihood and log priors are also given. We see that the true peptide
(highlighted in bold) is among the top estimated peptides. Although the spectrum has more
noise, our method was still able to identify the true peptide as being among the best choices.
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Table 6.3 The top estimated peptides from the MCMC algorithm along with their
corresponding log posterior densities, log likelihoood, log cleavage prior, log sequence
prior, and log κ1 and log κ2 prior for the peptide TGMSNV SK when using a simulated
spectrum with substantial noise.
Peptide Log Posterior Log Likelihood Log Cleavage Log Sequence Log κ1 Log κ2
Densities Prior Prior Prior Prior
TGMSAAASK 40.36 70.38 -8.15 -27.45 6.01 -0.74
TGMSGGVSK 39.60 71.46 -8.68 -28.31 5.90 -0.77
TGMSGVGSK 38.66 70.84 -8.67 -28.44 5.81 -0.88
SAMSNVSK 35.45 66.08 -9.62 -25.66 5.74 -1.09
TGMSNVSK 33.22 63.68 -9.56 -25.62 5.64 -0.92
TGMSNVSAG 27.10 63.40 -9.19 -31.85 5.32 -0.63
ASMSNVSK 21.70 52.06 -9.07 -25.62 5.01 -0.69
TGMSNGEK 21.40 48.65 -6.17 -25.62 4.98 -0.74
SAMSNVSQ 20.48 51.58 -6.40 -28.33 4.76 -1.13
Example 6.2
Here we set the parameters to be the same as in Example 6.1. We now generate a spectrum
for a peptide with a longer amino acid sequence. The generated spectrum is based on
the peptide Y HFEQSTV TSQPAR whose observed spectrum contains m/z values that
range from 235 to 1634 Da. The total number of true peaks is s = 26 and so s1 = 3,
s2 = 20, and s3 = 3 using boundary section proportions 0.1. Figure 6.6 shows the plot of
the simulated data versus the observed spectrum and theoretical spectrum. The simulated
spectrum is above the zero axis. The observed spectrum is plotted below the zero axis with
solid lines and the theoretical spectrum is plotted below the zero axis with dashed lines.
One can see the simulated spectrum mimics the observed spectrum reasonably well.
After the spectrum is simulated, we then applied our method to the simulated spectrum.
The starting peptide is HY FETDQATSKPVK, which was obtained from the results
from PepNovo when applied to the real data. The algorithm was run for 10000 iterations
and the best estimated peptide for the true peptide is Y HFEQSTV TSQPAR with a log
posterior density of 88.52 (up to a constant). Table 6.4 shows the top estimated peptides
for the Y HFEQSTV TSQPAR example using the simulated spectrum along with their
52








Figure 6.6 Simulated spectrum plotted against the observed spectrum and theoretical
spectrum. The simulated spectrum is plotted above the zero axis. The observed spectrum
is below the zero axis with solid lines and the theoretical spectrum is plotted below the
zero axis with dashed lines.
Table 6.4 The top estimated peptides from the MCMC algorithm along with their
corresponding log posterior densities, log likelihoood, log cleavage prior, log sequence
prior, log κ1 prior, and log κ2 prior for the peptide Y HFEQSTV TSQPAR when using
a simulated spectrum.
Peptide Log Posterior Log Likelihood Log Cleavage Log Sequence Log κ1 Log κ2
Densities Prior Prior Prior Prior
YHFEQSTVTSQPAR 88.52 141.08 -13.57 -44.63 5.44 0.19
YHFEQSTVTNTPVQ 86.87 145.87 -17.28 -47.56 5.67 0.16
GDKFEQSTVTSQPAR 85.00 147.05 -18.65 -49.15 5.62 0.14
YHFEQSTVTNTPAR 84.01 134.36 -12.12 -43.85 5.53 0.09
YHFEKSTVTSQPAR 83.47 140.44 -14.70 -48.14 5.76 0.12
YHFEQSTVTSKPAR 70.50 126.80 -15.02 -46.89 5.58 0.03
YHFEKSTVTSKPAR 59.67 118.56 -13.70 -50.41 5.00 0.22
YHFAWSTVTSKPAR 43.31 102.52 -15.31 -49.07 5.07 0.10
YHFAWSTVTSQPAR 41.81 102.71 -18.84 -46.80 4.63 0.11
corresponding estimated log posterior densities with the breakdown of the log posterior.
The log likelihood and log priors are also given. As in Example 6.1, we see that the true
peptide (highlighted in bold) is among the top estimated peptides. Here the best estimated
peptide is the true peptide.
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Once again, to how see our method is performing, we simulate a spectrum with minimal
noise and one with substantial noise for a peptide with a longer amino acid sequence. To
produce a generated spectrum with minimal noise, we decrease the values of b and as in
Example 6.1, we set the values to be b1 = b2 = b3 = 2. To produce a generated spectrum
with substantial noise for a peptide with a longer amino acid sequence, we increase the
values of b and as in Example 6.1, we set the values to be b1 = b2 = b3 = 10. Our method
was then applied to both generated spectra. For both examples the algorithm was run for
10000 iterations with a starting peptide ofHY FETDQATSKPVK, which was obtained
from the results from PepNovo.
Figure 6.7 show the plot of the simulated spectrum with minimal noise plotted against
the observed spectrum and theoretical spectrum. The best estimated peptide for the true








Figure 6.7 Simulated spectrum with minimal noise plotted against the observed
spectrum and theoretical spectrum. The simulated spectrum is plotted above the zero axis.
The observed spectrum is below the zero axis with solid lines and the theoretical spectrum
is plotted below the zero axis with dashed lines.
peptide when using minimal noise is Y HFEQSTV TSQPARwith a log posterior density
of 6.21 (up to a constant). Table 6.5 shows the top estimated peptides for the Y HFEQSTV TSQPAR
54
Table 6.5 The top estimated peptides from the MCMC algorithm along with their
corresponding log posterior densities, log likelihoood, log cleavage prior, log sequence
prior, log κ1 prior, and log κ2 prior for the peptide Y HFEQSTV TSQPAR when using
a simulated spectrum with minimal noise.
Peptide Log Posterior Log Likelihood Log Cleavage Log Sequence Log κ1 Log κ2
Densities Prior Prior Prior Prior
YHFEQSTVTSQPAR 6.21 55.98 -10.29 -47.30 5.99 0.22
YHFSEGSSVVSQPAR 4.40 62.07 -16.64 -47.08 5.86 0.19
YHFSEKTVTSQPAR 3.60 55.12 -10.29 -47.30 5.82 0.25
YHFSEGATTVSQPAR 2.45 60.22 -16.64 -47.08 5.79 0.16
NVSFSEGSSVVSQPAR -9.66 56.62 -22.93 -49.16 5.63 0.18
AWSVMAAGAGGFPRGES -22.94 50.69 -14.88 -64.42 5.55 0.12
YHFSEGATVTSQPAR -35.23 21.40 -15.42 -46.53 5.24 0.09
YNLGSENSPDCKVPQ -39.69 22.63 -14.04 -53.50 5.08 0.13
VTTFGGNLVMAAELID -41.07 22.13 -13.41 -54.85 4.88 0.18
LIAFFNGGGATCHEVD -41.45 29.23 -16.33 -59.10 4.72 0.04
example using the simulated spectrum with minimal noise along with their corresponding
estimated log posterior densities with the breakdown of the log posterior. The log likeli-
hood and log priors are also given. We see that the true peptide (highlighted in bold) is the
top estimated peptide as in Example 6.1 ensuring our method is performing substantially
accurately.
Figure 6.8 shows the plot of the simulated spectrum with substantial noise plotted
against the observed spectrum and theoretical spectrum. The best estimated peptide for
the true peptide when using substantial noise is Y HFEQSTV TQSPLN with a log pos-
terior density of 180.51 (up to a constant). Table 6.6 shows the top estimated peptides
for the Y HFEQSTV TSQPAR example using the simulated spectrum with substantial
noise along with their corresponding estimated log posterior densities with the breakdown
of the log posterior. The log likelihood and log priors are also given. Here the true peptide
was not identified in the top estimated peptides but there was more noise added into the
spectrum, causing our method not to identify it as one of the top choices.
6.2 POISSON NOISE STRUCTURE
A counting process is a stochastic process {N(t), t ≥ 0} where {N(t)} is the total number
of events that have occurred in a specified time interval, [0, t]. A Poisson process is a
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Figure 6.8 Simulated spectrum with substantial noise plotted against the observed
spectrum and theoretical spectrum. The simulated spectrum is plotted above the zero axis.
The observed spectrum is below the zero axis with solid lines and the theoretical spectrum
is plotted below the zero axis with dashed lines.
Table 6.6 The top estimated peptides from the MCMC algorithm along with their
corresponding log posterior densities, log likelihoood, log cleavage prior, log sequence
prior, log κ1 prior, and log κ2 prior for the peptide Y HFEQSTV TSQPAR when using
a simulated spectrum with substantial noise.
Peptide Log Posterior Log Likelihood Log Cleavage Log Sequence Log κ1 Log κ2
Densities Prior Prior Prior Prior
YHFEQSTVTQSPLN 180.51 241.92 -18.71 -49.14 5.75 0.68
YHFEKSTVTQSPAR 163.42 220.25 -14.52 -48.20 5.16 0.73
YHFEKSTVTSKPAR 157.52 218.14 -16.35 -50.41 5.45 0.69
YHFEQSTVTQSPAR 154.39 206.48 -13.09 -44.69 5.02 0.67
YHFEQSTTWQPAR 133.61 185.51 -14.11 -43.13 4.65 0.68
YHFEKSTTWQPAR 128.38 185.13 -15.42 -46.64 4.67 0.64
YHFEKSTVTSQPAR 122.15 177.13 -11.86 -48.14 4.46 0.57
YHFEKSTVTSPQAR 120.26 181.71 -16.35 -50.41 4.82 0.48
YHFEQSTSISQPAR 116.96 169.27 -12.00 -45.25 4.39 0.55
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type of counting process that has independent increments; that is, the number of events
in the process occurring in nonoverlapping intervals are independent random variables.
The time between pair of successive events follows an exponential distribution with rate
parameter θ (Doob, 1953; Raftery and Akman, 1986). By using a Poisson process, we can
generate noise peaks that are independent of the signal peak locations, and thus we explore
generating the noise peaks by using a Poisson process.
As with the Laplace noise structure, the spectrum is split into three sections. To deter-
mine the number of noise peaks needed for each section, the total number of m/z values,
denoted as q, that have intensity values above a specific threshold is first found from the
observed spectrum of the true peptide. Then q is split into three values, (q1, q2, and q3),
where these values will determine the number of noise peaks needed for each section. Due
to the processing of the spectrum by the mass spectrometer, the first section of the spec-
trum will have the fewest noise peaks and the middle section will have the most noise
peaks. To illustrate how to find the number of peaks needed for each section, consider a
peptide whose spectrum contains 100 m/z values. For the first section of the spectrum,
there will be q1 = 100× .25 = 25 noise peaks that are generated. The third section of the
spectrum will have q3 = 100 × .25 = 25 noise peaks. The middle section will then have
q2 = 100 − 25 − 25 = 50 noise peaks. The proportions 0.25 and 0.75 for each boundary
section were chosen based upon extensive numerical experimentation. To obtain the loca-
tions for the noise peaks for each section, the cumulative sum of randomly generated values
from an exponential distribution, shifted by a specified value c, is found by the following
algorithm:
1. Initialize t = 0.
2. Generate x ∼ Exp(θ)
3. Set t = t+ x.
4. Store t in t.
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5. Repeat qi times.
6. Compute t+ c,
where t is the vector of noise peaks for section i for i = 1, 2, 3. In order for the generated
noise peaks to havem/z values in the same range as the observed spectrum, we must set an
initial value to be added to the Poisson process. Recall the amino acid G has the smallest
mass of 57.0215 Da. Let maxmz be the largest m/z value for the observed spectrum. For
the first section, the value of c (denoted as c1) is found by c1 = 57+(maxmz−57)×0.1. The
value for c for the middle section (denoted as c2) is found by c2 = c1 +(maxmz−57)×0.2
and for the last section c (denoted as c3) is found by c3 = c1 +c2 +(maxmz−57)×0.3. The
proportions 0.1, 0.2. and 0.3 are chosen after experimentation. To demonstrate how to find
c, consider a peptide whose maximum m/z value is 1150. The values of c for each section
would be the following: c1 = 57+(1150−57)×0.1 = 166, c2 = 166+(1150−57)×0.2 =
385, and c3 = 166 + 385 + (1150− 57)× 0.30 = 879.
The full algorithm for obtaining the signal and noise peaks using a Poisson process with
a parameter θ is defined as
1. Determine the total number of true peaks, s, and compute τ by finding the b and y
ions, based on the given peptide.
2. Simulate signal peaks from a density f(xi) ∝ e−κ1|xi−τi| for i = 1, . . . , s.
3. Use an indicator function λi with probability function P (λ) =
∏p
i=1 P (λbi , λ
y
i ),
where p = s − 1 is the total number of b ions (or, equivalently, the number of y
ions) to determine the presence or absence of each signal peak.
4. For each of the three sections in the spectrum, compute the number of noise peaks
for each section of the spectrum.
5. Simulate noise peaks from the algorithm described above.
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When using a Poisson process to simulate the location of the noise peaks, we need to
choose the value of the fixed parameter θ. Figure 6.9 shows the plot of a generated spectrum
versus the observed spectrum and theoretical spectrum for a given peptide using different
values of θ. This illustrates how the choice of θ affects the location of the generated noise
peaks. The choice of θ for Figure 6.9 (a) is θ = 1/15, θ = 1.0 for Figure 6.9 (b), and
θ = 1/30 for Figure 6.9 (c). Increasing θ causes the location of the generated noise peaks
to create clusters of tightly spaced noise peaks. Decreasing the value of θ causes there to
be fewer noise peaks in the generated spectrum and thus it does not imitate the observed
spectrum as well.
































Figure 6.9 Simulated spectrum plotted against the observed spectrum and theoretical
spectrum. The simulated spectrum is plotted above the zero axis. The observed spectrum
is below the zero axis with solid lines and the theoretical spectrum is plotted below the
zero axis with dashed lines. Values for θ: (a) θ = 1/15, (b) θ = 1.0, (c) θ = 1/30.
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Example 6.3
The parameters must first be specified. We set κ1 = 50 and θ = 1/15. As in Example 6.1
and 6.1, we set the first elements of β and γ to be pb1 = 0.05 and py1 = 0.10 and all other
pbi and pyi to equal 0.80 for i = 2, . . . , p.
As in Example 6.1, we first generate a peptide with a short amino acid sequence. We
use the same peptide as in Example 6.2, TGMSNV SK. Recall the observed spectrum
contains m/z values that range from 123 to 749 Da. The total number of true peaks is
s = 14 and so s1 = 1, s2 = 12, and s3 = 1. The total number of m/z values in the
observed spectrum with intensity values above a threshold is q = 75 and so q1 = 19,
q2 = 37, and q3 = 19. Figure 6.10 shows the plot of the simulated data versus the observed
spectrum and theoretical spectrum when using the Poisson noise structure. The simulated
spectrum is plotted above the zero axis. The observed spectrum is plotted below the zero
axis with solid lines and the theoretical spectrum is plotted below the zero axis with dashed
lines. One can see the simulated spectrum mimics the observed spectrum reasonably well.
After the spectrum is generated, our method described in Chapter 4 is then applied to
the simulated spectrum. The starting peptide is GTMSGRSQ, which was obtained from
the results from PepNovo when applied to the real data. The algorithm was run for 10000
iterations and the best estimated peptide for the true peptide is SAMSNV SK with a log
posterior density of 12.60 (up to a constant). Table 6.7 shows the top estimated peptides
for the TGMSNV SK example using the simulated spectrum with Poisson noise structure
along with their corresponding estimated log posterior densities with the breakdown of the
log posterior. The log likelihood and log priors are also given. We see that the true peptide
(highlighted in bold) is among the top estimated peptides. Here it is the second best peptide
but notice the log posterior for the best estimated and the log posterior for the true peptide
is quite similar.
Once again, we need to ensure our algorithm is performing accurately, and so we sim-
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Figure 6.10 Simulated spectrum plotted against the observed spectrum and theoretical
spectrum when using the Poisson noise structure. The simulated spectrum is plotted above
the zero axis. The observed spectrum is below the zero axis with solid lines and the
theoretical spectrum is plotted below the zero axis with dashed lines.
Table 6.7 The top estimated peptides from the MCMC algorithm along with their
corresponding log posterior densities, log likelihoood, log cleavage prior, log sequence
prior, log κ1 prior, and log κ2 prior for the peptide TGMSNV SK when using a
simulated spectrum.
Peptide Log Posterior Log Likelihood Log Cleavage Log Sequence Log κ1 Log κ2
Densities Prior Prior Prior Prior
SAMSNVSK 12.60 40.61 -7.14 -25.66 5.41 -0.62
TGMSNVSK 11.30 43.79 -11.66 -25.62 5.33 -0.55
GTMSNVSK 9.79 40.27 -8.84 -26.39 5.35 -0.60
SAFANVSK 9.30 37.84 -8.20 -24.92 5.13 -0.54
SAAFNVSK 3.29 28.90 -6.18 -23.85 5.14 -0.72
SAFANVNT 3.11 35.72 -8.53 -28.61 5.12 -0.60
SAFANVKS 0.69 36.95 -7.88 -32.84 5.06 -0.60
SAFANVSQ -6.22 25.48 -8.16 -27.59 4.88 -0.83
SAMSNVSGA -40.97 -9.21 -7.63 -25.66 2.59 -1.06
TGMSNVSGA -61.57 -21.87 -9.56 -31.08 2.11 -1.16
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ulate two spectra; one with minimal noise and one with substantial noise. To decrease the
number of noise peaks, we decrease the values of q1, q2, and q3 by 15 and to increase the
number of noise peaks in the generated spectrum, we increase the values of q1, q2, and q3
by 15. Our method was then applied to both generated spectra. For both examples the
algorithm was run for 10000 iterations with a starting peptide of GTMSGRSQ, which
was obtained from the results from PepNovo.
Figure 6.11 shows the plot of the simulated spectrum with minimal noise plotted against
the observed spectrum and theoretical spectrum. The best estimated peptide for the true










Figure 6.11 Simulated spectrum with minimal noise plotted against the observed and
theoretical spectra when using the Poisson noise structure. The simulated spectrum is
plotted above the zero axis. The observed spectrum is below the zero axis with solid lines
and the theoretical spectrum is plotted below the zero axis with dashed lines.
peptide when using minimal noise is TGMSNV SK with a log posterior density of−2.03
(up to a constant). Table 6.8 shows the top estimated peptides for the TGMSNV SK ex-
ample using the simulated spectrum with minimal noise along with their corresponding
estimated log posterior densities with the breakdown of the log posterior. The log likeli-
hood and log priors are also given. We see that the true peptide (highlighted in bold) is the
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Table 6.8 The top estimated peptides from the MCMC algorithm along with their
corresponding log posterior densities, log likelihoood, log cleavage prior, log sequence
prior, and log κ1 and log κ2 prior for the peptide TGMSNV SK when using a simulated
spectrum with minimal noise.
Peptide Log Posterior Log Likelihood Log Cleavage Log Sequence Log κ1 Log κ2
Densities Prior Prior Prior Prior
TGMSNVSK -2.03 25.19 -6.57 -25.62 5.78 -0.81
TGMSRGSK -24.68 8.33 -6.50 -31.16 5.33 -0.67
SVFNKTQ -31.30 -1.63 -5.75 -28.69 5.22 -0.45
TGMSRGSQ -36.43 0.58 -8.07 -33.83 5.47 -0.58
TFQNVSGA -37.00 -4.01 -9.01 -28.40 5.19 -0.76
SVFNKSAA -50.01 -14.80 -8.04 -31.34 4.96 -0.79
TGMGDKSQ -50.85 -10.26 -14.22 -31.16 5.33 -0.54
TFQGGVSGA -52.06 -16.93 -8.38 -31.25 5.12 -0.62
SFNEGGAAA -53.32 -19.94 -8.13 -29.22 4.24 -0.27
NSVAAHPQ -54.21 -22.24 -7.99 -29.14 5.38 -0.22
top estimated peptide indicating our method is performing substantially accurately.
Figure 6.12 shows the plot of the simulated spectrum with substantial noise plotted
against the observed spectrum and theoretical spectrum. The best estimated peptide for
the true peptide when using substantial noise is SAMSGGV SK with a log posterior
density of 17.97 (up to a constant). Table 6.9 shows the top estimated peptides for the
TGMSNV SK example using the simulated spectrum with substantial noise along with
their corresponding estimated log posterior densities with the breakdown of the log pos-
terior. The log likelihood and log priors are also given. We see that the true peptide
(highlighted in bold) is among the top estimated peptides. Although the spectrum has more
noise peaks, our method was still able to identify the true peptide as being among the best
choices.
Example 6.4
For the second example, we keep the parameters the same as specified in Example 6.3.
We consider a peptide with a longer amino acid structure. We generate a spectrum for
the peptide Y HFEQSTV TSQPAR, which is the same as in Example 6.2. Recall the
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Figure 6.12 Simulated spectrum with substantial noise plotted against the observed
spectrum and theoretical spectrum when using the Poisson noise structure. The simulated
spectrum is plotted above the zero axis. The observed spectrum is below the zero axis with
solid lines and the theoretical spectrum is plotted below the zero axis with dashed lines.
Table 6.9 The top estimated peptides from the MCMC algorithm along with their
corresponding log posterior densities, log likelihoood, log cleavage prior, log sequence
prior, log κ1 prior, and log κ2 prior for the peptide TGMSNV SK when using a
simulated spectrum with substantial noise.
Peptide Log Posterior Log Likelihood Log Cleavage Log Sequence Log κ1 Log κ2
Densities Prior Prior Prior Prior
SAMSGGVSK 17.97 49.44 -7.79 -28.35 5.01 -0.34
TGMSGGVSK 14.31 46.91 -8.81 -28.31 4.85 -0.34
TGMSNVSK 0.55 29.41 -7.56 -25.62 4.86 -0.55
TGMSNVSAG -3.03 33.35 -8.72 -31.85 4.76 -0.57
TGSMNVSK -3.33 25.64 -8.02 -25.15 4.79 -0.59
TGSMGGVSK -3.44 30.09 -8.81 -28.31 4.22 -0.64
TGMSNVSGA -6.45 30.13 -9.84 -31.04 4.98 -0.69
TMGSNVSK -7.21 21.85 -7.56 -25.62 4.82 -0.70
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observed spectrum contains m/z values that range from 235 to 1634 Da. The total number
of true peaks is s = 26 and so s1 = 3, s2 = 20, and s3 = 3. The total number of m/z
values in the observed spectrum with intensity values above a threshold is q = 157 and so
q1 = 39, q2 = 79, and q3 = 39 (up to a constant).
Figure 6.13 shows the plot of the simulated data versus the observed spectrum and
theoretical spectrum when using the Poisson noise structure. The simulated spectrum is
plotted above the zero axis. The observed spectrum is plotted below the zero axis with
solid lines and the theoretical spectrum is plotted below the zero axis with dashed lines.
One can see the simulated spectrum mimics the observed spectrum reasonably well. After










Figure 6.13 Simulated spectrum plotted against the observed spectrum and theoretical
spectrum when using the Poisson noise structure. The simulated spectrum is plotted above
the zero axis. The observed spectrum is below the zero axis with solid lines and the
theoretical spectrum is plotted below the zero axis with dashed lines.
the spectrum is simulated, our method is applied to the simulated spectrum. The starting
peptide is HY FETDQATSKPVK, which was obtained from the results from PepNovo
when applied to the real data. The algorithm was run for 10000 iterations and the best
estimated peptide for the true peptide is Y HFGATMSV EGQPAV G with a log poste-
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Table 6.10 The top estimated peptides from the MCMC algorithm along with their
corresponding log posterior densities, log likelihoood, log cleavage prior, log sequence
prior, log κ1 prior, and κ2 prior for the peptide Y HFEQSTV TSQPAR when using a
simulated spectrum.
Peptide Log Posterior Log Likelihood Log Cleavage Log Sequence Log κ1 Log κ2
Densities Prior Prior Prior Prior
YHFGATMSVEGQPAVG 10.69 76.27 -13.98 -55.72 4.04 0.09
YHFQTFAVEGQPAVG 8.55 74.36 -17.51 -52.15 3.76 0.10
YHFEQSTVTSQPAR 6.41 77.81 -20.77 -54.41 3.67 0.10
YHFGATMEGEGQPAVG -3.28 67.19 -20.01 -53.99 3.40 0.11
YHFGAGMETEGQPAVG -9.41 59.44 -18.46 -53.92 3.48 0.05
YHFGATSETEGQPAVG -10.08 59.58 -19.57 -53.74 3.64 0.01
YHFGAGMETADQPAVG -13.19 59.62 -22.10 -54.17 3.41 0.05
YHFGASTETEGQPAVG -17.15 51.30 -17.65 -54.01 3.25 -0.03
YHFGAGMETADQPAR -21.03 39.27 -16.27 -47.09 3.13 -0.06
YHFKTDTVTSQPAR -30.34 32.64 -17.18 -48.78 3.00 -0.03
YHFGATFAVEGQPAVG -47.16 18.95 -20.45 -48.14 2.67 -0.17
rior density of 10.69 (up to a constant). Table 6.10 shows the top estimated peptides for
the Y HFEQSTV TSQPAR example using the simulated spectrum with Poisson noise
structure along with their corresponding estimated log posterior densities with the break-
down of the log posterior. The log likelihood and log priors are also given. We see that the
true peptide (highlighted in bold) is among the top estimated peptides. Here it is the third
best peptide.
Once again, we need to ensure our algorithm is performing accurately, and so we sim-
ulate two spectra: one with minimal noise and one with substantial noise. To decrease the
number of noise peaks, we decrease the values of q1, q2, and q3 by 15 and to increase the
number of noise peaks in the generated spectrum, we increase the values of q1, q2, and q3
by 15. Our method was then applied to both generated spectra. For both examples the al-
gorithm was run for 10000 iterations with a starting peptide ofHY FETDQATSKPVK,
which was obtained from the results from PepNovo.
Figure 6.14 shows the plot of the simulated spectrum with minimal noise plotted against
the observed spectrum and theoretical spectrum. The best estimated peptide for the true
peptide when using minimal noise is Y HFEQSTV TSPQAR with a log posterior den-
sity of 50.94 (up to a constant). Table 6.11 shows the top estimated peptides for the
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Figure 6.14 Simulated spectrum with minimal noise plotted against the observed and
theoretical spectra when using the Poisson noise structure. The simulated spectrum is
plotted above the zero axis. The observed spectrum is below the zero axis with solid lines
and the theoretical spectrum is plotted below the zero axis with dashed lines.
Y HFEQSTV TSQPAR example using the simulated spectrum with minimal noise along
with their corresponding estimated log posterior densities with the breakdown of the log
posterior. The log likelihood and log priors are also given. We see that the true peptide
(highlighted in bold) is among the top estimated peptides. Here it is the second best esti-
mated peptide, but do note the log posterior for true peptide is not that much smaller than
the best estimated peptide, confirming that our method is performing adequately well.
Figure 6.15 shows the plot of the simulated spectrum with substantial noise plotted
against the observed spectrum and theoretical spectrum. The best estimated peptide for
the true peptide when using substantial noise is Y HFEQSTV TSAGPAR with a log
posterior density of 141.50 (up to a constant). Table 6.12 shows the top estimated peptides
for the Y HFEQSTV TSQPAR example using the simulated spectrum with substantial
noise along with their corresponding estimated log posterior densities with the breakdown
of the log posterior. The log likelihood and log priors are also given. We see that the true
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Table 6.11 The top estimated peptides from the MCMC algorithm along with their
corresponding log posterior densities, log likelihoood, log cleavage prior, log sequence
prior, log κ1 prior, and log κ2 prior for the peptide Y HFEQSTV TSQPAR when using
a simulated spectrum with minimal noise.
Peptide Log Posterior Log Likelihood Log Cleavage Log Sequence Log κ1 Log κ2
Densities Prior Prior Prior Prior
YHFEQSTVTSPQAR 50.94 106.71 -16.09 -45.21 5.01 0.52
YHFEQSTVTSQPAR 48.16 101.54 -14.20 -44.63 4.96 0.49
YHFEQSTVTSKPAR 44.39 100.61 -14.65 -46.89 4.88 0.44
YHFEQSTVTSKPNL 41.20 103.98 -16.84 -50.91 4.55 0.41
YHFEQSTPCSPAGAR -9.05 58.66 -14.34 -58.55 4.78 0.39
YHFEQSTPCSAGPAR -22.90 45.73 -15.31 -58.57 4.77 0.48
YHFEQSTPSSSGPAR -42.21 20.86 -20.61 -47.18 4.40 0.32
YHFEQSPTSSSGPAR -46.12 16.82 -16.76 -50.69 4.23 0.29
YHFEQSTPCSPQAR -47.87 20.47 -14.34 -58.55 4.18 0.36
YHFEKSPTSSSGPAR -68.16 0.13 -15.63 -57.43 4.33 0.45










Figure 6.15 Simulated spectrum with substantial noise plotted against the observed
spectrum and theoretical spectrum when using the Poisson noise structure. The simulated
spectrum is plotted above the zero axis. The observed spectrum is below the zero axis with
solid lines and the theoretical spectrum is plotted below the zero axis with dashed lines.
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Table 6.12 The top estimated peptides from the MCMC algorithm along with their
corresponding log posterior densities, log likelihoood, log cleavage prior, log sequence
prior, log κ1 prior, and log κ2 prior for the peptide Y HFEQSTV TSQPAR when using
a simulated spectrum with substantial noise.
Peptide Log Posterior Log Likelihood Log Cleavage Log Sequence Log κ1 Log κ2
Densities Prior Prior Prior Prior
YHFEQSTVTSAGPAR 141.50 194.83 -18.51 -47.21 5.75 0.45
YHFEAGSTVTSQPAR 140.62 190.67 -15.33 -47.04 5.70 0.46
YHFEQSTVTSGAPAR 140.22 192.03 -17.16 -47.31 5.92 0.40
YHFEAGSTVTSGAPAR 135.46 190.34 -17.10 -49.72 5.58 0.41
YHFEAGSTVTSKPAR 133.49 183.83 -13.50 -49.31 5.87 0.36
YHFEQSTVTSQPAR 128.28 173.90 -13.44 -44.63 5.86 0.37
YHFEQSTVMGQPAR 116.28 165.56 -15.99 -45.28 5.66 0.33
peptide (highlighted in bold) is among the top estimated peptides. Although the spectrum
has more noise peaks, our method was still able to identify the true peptide as being among
the best choices.
6.3 COMPARISON OF NOISE STRUCTURE
With moderate noise, both the methods perform equally well for both noise structures for
peptides with both short and long amino acid sequences. When generating minimal noise,
once again both noise structures performed equally well for peptides with short and long
amino acid structures. With minimal noise, the true peptide was identified in all cases
except with the Poisson noise structure for a peptide with a longer amino acid sequence,
but the true peptide was estimated as the second best with a log posterior similar to the best
estimated peptide.
For peptides with short and long amino acid sequences, using either noise structure,
our method performed equally well for all levels of noise tried. The noise generated in the
spectrum is not completely realistic since certain peak features like isotopic peak, adducts,
and post translational modifications are not included in the noise and so the noise generated
is somewhat artificial. Although the noise generated in the spectrum may not be realistic,
the methods are promising. An advantage of using a Laplace noise structure is that our
model would be an approximation to a generative model. Unlike a discriminative model,
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a generative model allows one to generate samples from the joint distribution. Generative
models are more flexible since they are full probabilistic models of all variables and can be
used to simulate values of any variable in the model (Singla and Domingos, 2005). Note




Most peptides in the PNNL dataset described in Section 1.1 are of length 8 to 20 amino
acids. Our data include some relatively longer peptides due to the type of equipment used to
process the data. Recall the equipment used was a LTQ Orbitrap mass spectrometer, which
is a hybrid machine composed of a linear ion trap mass spectrometer and the Orbitrap
mass analyzer that uses a fast Fourier transform algorithm (Yates et al., 2009). The dataset
contains 1,206 peptides with lengths ranging from 7 to 31 amino acids and an average
length of 15.16. The data are doubly charged and the total mass for each peptide is given.
The dataset contains a set of masses and corresponding intensities with an average intensity
value of 50.7.
The data must first be pre-processed. We choose to remove the doubly charged parent
ion from the dataset. A parent ion is the fragment ion generated in mass spectrometry
before the ion is broken apart into further ions. The m/z value of the doubly-charged
ion is
∑K
i=1 m(pi) + 1
2 . Therefore, we remove the peak at that m/z value. After extensive
numerical experimentation, we found that using the 75th percentile to calculate the constant
and moving threshold works well. This means we use the observed m/z values in the data
that have corresponding observed intensity values above the threshold value in T . The mass
spectrometer is not always accurate and this can cause the ion fragments that are detected
to be slightly shifted from their theoretical position. Therefore, we use a tolerance level
of 0.5 Da. That is, we tolerate the ion peak locations up to ±0.5 Da from their theoretical
positions. We set the initial components of β and γ to be pb1 = 0.05 and py1 = 0.10.
We set these probabilities low because the mass spectrometer rarely captures the first b
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and y ion. We set all other pbi and pyi to equal 0.80 for i = 2, . . . , p. We must also
specify the hyperparameters in the Gamma prior distribution for κ1 and κ2. After extensive
numerical experimentation, the values of a1, b1, a2, and b2 were set to be 5.5, 0.1, 3, and
1/0.01, respectively. Figure 7.1 portrays the conditional posterior density function for κ1
and Figure 7.2 portrays the prior density function for κ2, given S1 = 0.16 and S2 = 7.89,
which are fairly typical values of S1 and S2. Section 7.4 goes into more detail about the
choice of the tuning parameters through exploratory analysis.





















Figure 7.1 The conditional posterior density function for κ1, given S1 = 0.16 and
S2 = 7.89.
7.1 EXAMPLE 1
Consider the peptide TGMSNV SK. Figure 7.3 is a plot of the observed spectrum for the
peptide TGMSNV SK. The theoretical spectrum is plotted below the zero axis. One can
see that the theoretical spectrum aligns nicely with the observed spectrum. Note that there
is quite a bit of noise in the center of the graph even after thresholding.
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Figure 7.2 The conditional posterior density function for κ2, given S1 = 0.16 and
S2 = 7.89.






















Figure 7.3 The observed spectrum plotted against the theoretical spectrum for the
peptide TGMSNV SK. The theoretical spectrum is plotted below the zero axis and the
observed spectrum is plotted above the zero axis.
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Table 7.1 The top estimated peptides from the MCMC algorithm along with their
corresponding log posterior densities for the peptide TGMSNV SK when using a
random starting peptide.











Using the initial iterative sub-algorithm, we obtain a starting peptide of IEY GGGID,
which has a total mass that is within 0.5 Da of the weight of the true peptide. Running the
algorithm for 10,000 iterations, we estimate the true peptide to be TMTISASL with a log
posterior density of -18.16 (up to a constant). Table 7.1 shows the top estimated peptides
for the TGMSNV SK example along with their corresponding estimated log posterior
densities when the starting peptide is IEY GGGID. One can see the starting peptide
is far from the true peptide and when only running the algorithm for 10,000 iterations,
our method did not capture the true peptide. Starting from a completely random place is
idealistic, but it may not be best in practice due to the fact there is such a large state space.
Now using the results from PepNovo, we obtain a starting peptide of TGFAGGV SGA,
which has a total mass that is within 0.5 Da of the weight of the true peptide. Running the
algorithm for 10,000 iterations, we obtain the best estimated for the true peptide to be
TGMSGGV SK with a log posterior density of 14.79 (up to a constant). Table 7.2 shows
the top estimated peptides for the TGMSNV SK example along with their corresponding
estimated log posterior densities with the breakdown of the log posterior. The log likeli-
hood and log priors are also given. We see that the true peptide is among the top estimated
peptides. Here it is the third best peptide. The log posterior for the first three best esti-
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Table 7.2 The top estimated peptides from the MCMC algorithm along with their
corresponding log posterior densities, log likelihoood, log cleavage prior, log sequence
prior, log κ1 prior, and log κ2 prior for the peptide TGMSNV SK. The true peptide is in
bold.
Peptide Log Posterior Log Likelihood Log Cleavage Log Sequence Log κ1 Log κ2
Densities Prior Prior Prior Prior
TGMSGGVSK 14.79 49.16 -10.47 -28.28 4.67 -0.29
TGMSGGSVK 14.17 48.10 -10.19 -28.31 5.00 -0.43
TGMSNVSK 11.27 39.63 -8.92 -24.10 5.02 -0.37
TGAFGGSVK -0.31 33.37 -10.36 -27.43 4.60 -0.50
TGAFGGWK -8.30 24.63 -10.41 -26.68 4.60 -0.43
TGAFNWK -11.00 14.06 -6.46 -22.83 4.72 -0.50
TGMSNWK -18.39 10.00 -8.47 -24.01 4.72 -0.64
TGMSAKTK -36.00 -1.57 -9.25 -28.20 3.84 -0.82
TGMANTTK -36.07 -2.29 -7.93 -28.60 3.27 -0.53
TGMAKSTK -37.25 -3.11 -7.93 -28.60 2.93 -0.55
mated peptides is fairly similar. In Figure 7.3 that we see there is additional noise in the
center of the spectrum that causes the value of S2 for the true peptide to be larger, and the
difference in the log likelihood of the best estimated parameter and the true peptide can
be seen in Table 7.2. Also, note the difference in the sequence prior for the best estimated
peptide and the true peptide implying the amino acid sequence TGMSGGV SK is more
probable than the amino acid sequence TGMSNV SK. Figure 7.4 is the trace plot of the
log posterior versus the number of iterations. One can see the chain has converged to its
stationary distribution. Figure 7.5 is the trace plot of log κ1 versus the number of iterations
and Figure 7.6 is the trace plot of log κ2 versus the number of iterations. We see the κ1 and
κ2 samples converge to their stationary distribution.
To ensure our method is obtaining similar results for various starting peptides, we look
at results from using different starting peptides that we obtain from PepNovo. Consider the
starting peptides: SAMYHSK, TGAFGRSK, andGTFANEGK. Table 7.3 shows the
top estimated peptides along with their corresponding log posterior densities for the above
starting peptide values. One can see that the results are similar and that the true peptide
(highlighted in bold in the table) is captured and is in the top 10 of the estimated peptides
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Figure 7.4 Trace plot of the log posterior for the peptide TGMSNV SK.













Figure 7.5 Trace plot of log κ1 for the peptide TGMSNV SK.
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Figure 7.6 Trace plot of log κ2 for the peptide TGMSNV SK.
Table 7.3 The top estimated peptides from the MCMC algorithm along with their
corresponding log posterior densities for the peptide TGMSNV SK for three different
starting peptides. The true peptide is in bold.
Starting Peptide
SAMYHSK TGAFGRSK GTFANEGK
Peptide Log Posterior Peptide Log Posterior Peptide Log Posterior
TSTGGSVSK 2.40 TGSSSGLSK 0.32 TGMSGGVSGA 4.47
TSTSGGVSK -1.01 TGSSSGISK -0.15 TGSTSGVSGA 3.23
TGMSNSVK -12.65 SAMSNVSK -6.19 TGMGSGVSGA 0.91
TSTSNVSK -14.86 SAMSNADK -6.92 TGMSGGVSAG -.00039
AAFSNVSK -30.98 SANFAVSK -7.13 TGMSGGVSK -4.59
AAFKDGSK -41.49 TGMSNSVK -7.84 ASMSGGVSK -9.50
AAFGWGSK -46.46 TGFANVSK -9.91 TGMSNVSK -13.39
AAFYHSK -47.15 SASSSAVSK -10.04 TGMSNSVK -15.51
SAMYHSK -49.33 TGSSSAVSK -10.54 SAMSNSVK -28.03
SDSYHSK -57.06 TGMSNVSQ -13.64 SAFANSVK -40.82
in all three cases. The log posterior densities are also similar in the three cases.
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7.2 EXAMPLE 2
Consider a second peptide, DLV ESAPAALK. Figure 7.7 is a plot of the observed spec-
trum for the peptide DLV ESAPAALK. The theoretical spectrum is plotted below the
zero axis. One can see that the theoretical spectrum aligns nicely with the observed spec-
trum.





















Figure 7.7 The observed spectrum plotted against the theoretical spectrum for the
peptide DLV ESAPAALK. The theoretical spectrum is plotted below the zero axis and
the observed spectrum is plotted above the zero axis.
Using the initial iterative sub-algorithm, we obtain a starting peptide ofHMRAMPDQQ,
which has a total mass that is within 0.5 Da of the weight of the true peptide. Running the
algorithm for 10,000 iterations, we estimate the true peptide to be IAAAAGAAGGAANK
with a log posterior density of 18.08 (up to a constant). Table 7.4 shows the top estimated
peptides for the DLV ESAPAALK example along with their corresponding estimated
log posterior densities when the starting peptide is HMRAMPDQQ. As in Example 1
in Section 7.1, the starting peptide is far from the true peptide and when only running the
algorithm for 10,000 iterations, our method did not place the true peptide among the best
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Table 7.4 The top estimated peptides from the MCMC algorithm along with their
corresponding log posterior densities for the peptide DLV ESAPAALK when using a
random starting peptide.












Here we obtain an initial peptide of DLV ESY FLK from the PepNovo results. Run-
ning the algorithm for 10,000 iterations, we obtain the estimated true peptide to be IDV ESAPAALK
with a log posterior density of 65.92 (up to a constant). Table 7.5 shows the top estimated
peptides for the DLV ESAPAALK example along with their corresponding estimated
log posterior densities and the breakdown of the log posterior. The log likelihood and log
priors are also given. We see that the true peptide is in the list of the top estimated pep-
tides. Here it is the second best peptide. Note that the log posterior for the first three best
estimated peptides is fairly similar. In Figure 7.7 we see there is additional noise in the
center of the spectrum that causes the value of S2 for the true peptide to be larger. Notice
in Table 7.5 the difference in the log likelihood of the best estimated parameter and the true
peptide, causing our method not to choose the true peptide as the best estimated peptide.
Figure 7.8 is the trace plot of the log posterior versus the number of iterations. One can
see the chain has converged to its stationary distribution. Figure 7.9 is the trace plot of log
κ1 versus the number of iterations and Figure 7.10 is the trace plot of log κ2 versus the
number of iterations, respectively. Once again, we see the κ1 and κ2 samples converge to
their stationary distribution.
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Table 7.5 The top estimated peptides from the MCMC algorithm along with their
corresponding log posterior densities, log likelihoood, log cleavage prior, log sequence
prior, log κ1 prior, and log κ2 prior for the peptide DLV ESAPAALK.
Peptide Log Posterior Log Likelihood Log Cleavage Log Sequence Log κ1 Log κ2
Densities Prior Prior Prior Prior
IDVESAPAALK 65.92 103.28 -11.69 -31.12 5.11 0.34
DLVESAPAALK 62.26 100.01 -11.64 -31.26 4.85 0.32
NGGVESAPAALK 61.35 103.55 -12.16 -35.39 5.11 0.23
DLVESAAPALK 54.92 91.64 -10.23 -31.26 4.53 0.24
DIVESAPAALK 49.50 83.52 -7.74 -31.63 5.26 0.10
EPDDSAPAALK 53.16 88.85 -9.39 -31.26 4.73 0.23
ETILSAPAALQ 44.88 85.41 -10.03 -35.31 4.61 0.22
DIVESAPAAIK 44.27 78.78 -7.74 -31.63 4.79 0.07
ETILSAPAALK 42.34 83.38 -14.27 -31.75 4.85 0.12
ETVITAPAALK 39.42 74.75 -8.44 -31.82 4.70 0.23













Figure 7.8 Trace plot of the log posterior for the peptide DLV ESAPAALK.
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Figure 7.9 Trace plot of log κ1 for the peptide DLV ESAPAALK.





















Figure 7.10 Trace plot of log κ2 for the peptide DLV ESAPAALK.
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We look at results from using different starting peptides that we obtain from Pep-
Novo. Consider the starting peptides: DLV ESAPAPSK, LDV TDAPAALK, and
PMV EGTPAALQ. Table 7.6 shows the top estimated peptides along with their cor-
responding log posterior densities for the above starting peptide values. As in Example 1
in Section 7.1, the results are similar and that the true peptide (highlighted in bold in the
table) is among the best choices in each case, and the log posterior densities are also similar
in the three cases.
7.3 MORE EXAMPLES WITH REAL PEPTIDES
In this section, we look at 10 more peptides whose peptide sequences are of different
lengths. Tables 7.7 - 7.16 show the top estimated peptides obtained from our MCMC
algorithm along with their corresponding log posterior densities for different peptides. The
starting peptide, obtained from PepNovo, is provided for each table, and if the true peptide
is in the list, it will be highlighted in bold. In these examples, the true peptide is captured
in the list of top estimated peptides in all cases but two.
7.4 EXPLORING TUNING PARAMETERS
Extensive experimentation showed that using a threshold of 75% works well. We looked
at several other threshold values to see which optimized the results. Table 7.17 shows
the top estimated peptides along with their corresponding log posterior densities for the
peptide TGMSNV SK when using a threshold of 50% and 65% with a starting peptide
of SAMYHSK, and Table 7.18 shows the top estimated peptides along with their cor-
responding log posterior densities for the peptide TGMSNV SK when using a thresh-
old of 85% and 95% with a starting peptide of SAMYHSK. Table 7.19 shows the top
estimated peptides along with their corresponding log posterior densities for the peptide
DLV ESAPAALK when using a threshold of 50% and 65% with a starting peptide of






































































































































































































































































































































































































































































































































Table 7.7 The top estimated peptides from the MCMC algorithm for the true peptide
AQLQEIAQTK when using the starting peptide KALQNQAQTQ along with their
corresponding log posterior densities.











Table 7.8 The top estimated peptides from the MCMC algorithm for the true peptide
SILSELV R when using the starting peptide AELSGNAV R along with their
corresponding log posterior densities.








Table 7.9 The top estimated peptides from the MCMC algorithm for the true peptide
SV ANAEQMDR when using the starting peptide WANAKEMDR along with their
corresponding log posterior densities.








Table 7.10 The top estimated peptides from the MCMC algorithm for the true peptide
V SEGQTV R when using the starting peptide SVWQSLR along with their
corresponding log posterior densities.









Table 7.11 The top estimated peptides from the MCMC algorithm when using the
starting peptide TNV FALPDV V GV LTK for the true peptide
AFNEALPLTGV V LTK along with their corresponding log posterior densities.






Table 7.12 The top estimated peptides from the MCMC algorithm when using the
starting peptide GY AGDGDSDSEV Q for the true peptide GY AGDTATTSEV K
along with their corresponding log posterior densities.











Table 7.13 The top estimated peptides from the MCMC algorithm for the true peptide
LV SSPSTLNPGTNV AK when using the starting peptide
PDSSPSDPDSTLPNR along with their corresponding log posterior densities.











Table 7.14 The top estimated peptides from the MCMC algorithm for the true peptide
MPPTEGETGGQV LGSK when using the starting peptide
MPPTEGETLEV TRK along with their corresponding log posterior densities.












Table 7.15 The top estimated peptides from the MCMC algorithm when using the
starting peptide GAASDV LSLGGK for the true peptide SGPLAGY PV V DLGV R
along with their corresponding log posterior densities.











Table 7.16 The top estimated peptides from the MCMC algorithm when using the
starting peptide GHY FEQTWTSQPVK for the true peptide
Y HFEQSTV TSQPAR along with their corresponding log posterior densities.












Table 7.17 The top estimated peptides from the MCMC algorithm along with their
corresponding log posterior densities for the peptide TGMSNV SK for a threshold of




Peptide Log Posterior Peptide Log Posterior
TGGATTGMGA 2.56 SSDSNVSK 5.54
TGGATTTSK 1.63 TGMSGGVSK 5.46
TGGATDSSK 1.39 SAMSGGVSK 3.01
TGGATTTSAG 0.74 TGAFSNVK 2.56
TGGATTSASA -1.34 TGMSSNVK 1.72
TGGASDTSAG -3.13 TGMSNVSQ -2.47
TGGATTTGSA -3.39 TGFANVSK -2.68
TGGASDTSK -3.52 TGMSNVSGA -3.55
GTGATTGMK -7.33 SSDSNVSQ -3.94
GTGATASMK -8.40 TGMSNVSK -5.39
sponding log posterior densities for the peptide DLV ESAPAALK when using a thresh-
old of 85% and 95% with a starting peptide of DLV ESY FLK. One can see that as the
threshold is decreased, the estimated peptides become less similar to the true peptide. This
happens because as we lower the threshold, more noise enters the observed spectrum and
the value of S2 in the likelihood is greatly increased. Therefore, our algorithm cannot find
the true peptide. As the threshold is increased, at a certain point the estimated peptides be-
come less similar to the true peptide. Although there is less noise in the observed spectrum
when the threshold is increased, signal peaks may be removed from the observed spectrum
with a large threshold. Thus, our algorithm will not be able to correctly to identify the
true peptide. Using a threshold of 75% removes many noisy peaks while still retaining the
signal peaks.
Although we used a tolerance of 0.5 Da like PepNovo, we explored using a smaller
tolerance and larger tolerances. For every peptide in the data set, we calculated the mass for
each ion type and found the average percentage of ion presence within a specific tolerance.
Table 7.21 gives the average percentage of ion presence for different tolerances for each
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Table 7.18 The top estimated peptides from the MCMC algorithm along with their
corresponding log posterior densities for the peptide TGMSNV SK for a threshold of




Peptide Log Posterior Peptide Log Posterior
TGSTSGVSQ -0.33 TGMSASQAA -1.07
TGMSNVSK -4.44 TGMSSAQAA -1.20
TGMSNVSQ -10.98 TGMSAQSAA -10.71
TGMGSGVSQ -13.96 TGMSASAAGA -25.87
TTGSMNVSK -19.48 TGMSASAAK -29.95
TGAFNVSK -30.62 TGMSATQK -31.80
SASQSSEK -34.06 TGMSDGQK -34.02
SASQTDSK -35.97 TGSMDGQK -35.23
SAAFNVSK -42.30 TGSFVGQK -36.65
SASMNVSK -47.57 TGSFFHK -38.82
Table 7.19 The top estimated peptides from the MCMC algorithm along with their
corresponding log posterior densities for the peptide DLV ESAPAALK for a threshold




Peptide Log Posterior Peptide Log Posterior
EVVESGTGAHK 113.62 SLGAAGSGVAPVK 62.26
EVVESASAGHK 110.98 AEGAAGSGVAPVK 51.72
EVVESASGAHK 106.83 AEGAAGSINPVK 50.43
EVVESAGSAHK 102.86 AEGAGASIVPNK 50.24
NNVESASAGHK 95.83 SLGAAGSGGIPVK 50.12
IAGTNSTGETY 95.01 LKSQSIYFK 38.91
EVVESASAGHQ 93.12 AEGAGASINPVK 38.65
MPVESTGETY 92.07 AEKQSIYFK 34.88
MPVESASETY 91.56 AEKQSIVPNK 34.42
QLTGGSTGETY 90.07 AEKGASIVPNK 31.50
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Table 7.20 The top estimated peptides from the MCMC algorithm along with their
corresponding log posterior densities for the peptide DLV ESAPAALK for a threshold




Peptide Log Posterior Peptide Log Posterior
AQAKTPQELK -20.19 IDVDGASQVPI 5.20
AQQATPQELK -24.62 LDVDGASQVPI 1.13
HSTMHMELK -35.70 IDVDTNQVPI 0.47
HSTDRQELK -39.48 ILTDTNQVPI -11.17
HSCATPQELK -45.61 ILTDTNINPL -15.82
HSTVDGQELK -46.21 ILTDTNINPI -16.756
HSCLVGQELK -46.60 ILTDTIMPPL -17.14
HSCEHMELK -51.43 ILTDTIMPPI -27.62
DIVEHMELK -56.86 LLTDTIMPPI -37.11
DIVEHLFLK -72.59 LDVDTIMPPI -37.30
ion type. One can see that after a tolerance of 0.2 Da, the percentage of ion presence
tends to level off for the tolerances. Although the percentage of ion presence is increased
when the tolerance is increased, the room for error also increases. There are some other
ion types such as b − H2O and b − NH3 and possibly y − H2O, y2 and y − NH3 whose
presences are detected in the spectrum. Including these ions in the model may provide
better identification of the true peptide. Further exploration of other ion types is discussed
in Section 8.1.
We then explored how different tolerances affected the choice of the estimated peptides.
Table 7.22 shows the top estimated peptides along with their corresponding log posterior
densities for the peptide TGMSNV SK when using a tolerance of 0.1 Da and 1.0 Da and
with a starting peptide of SAMYHSK. Table 7.23 shows the top estimated peptides along
with their corresponding log posterior densities for the peptide DLV ESAPAALK when
using a tolerance of 0.1 Da and 1.0 Da and with a starting peptide of DLV ESY FLK.
Using a small tolerance like 0.1 Da hardly allows for any error in the mass spectrometer. In
order for the true peptide to be estimated correctly using a tolerance of 0.1 Da, the observed
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spectrum would need to be aligned almost perfectly with the observed spectrum. A large
tolerance like 1.0 Da would allow more room for error but it would expand the parameter
space that needs to be searched, which could prevent the algorithm from finding the true
peptide in an efficient manner.
7.5 RESULT COMPARISONS
An important goal is to quantify objectively how our method performs relative to its com-
petitors. Here we compare our results with those of PepNovo. We will use the results from
PepNovo using both the rank score and PepNovo score. Since our method hopes to identify
peptides that have not been cultured, we do not compare our results to that of SEQUEST
and MASCOT. We will not make a distinction between the amino acids I and L because
they have identical masses of 113.084. Although PepNovo does not make a distinction
between the amino acids K and Q because the difference in their masses is only a minute
difference of 0.04 Da, we will make the distinction.
Our comparison method looks at the minimum number of switches in the amino acid
sequence of the peptide that it takes to obtain the true peptide. Switches are only consid-
ered if the total mass remains within 0.5 Da of the total mass of the true peptide. If the
best estimated peptide is the truth, then minimum number of switches would be zero. To
illustrate this comparison method, consider the true peptide V SEGQTV R with the best
estimated peptide WEGQTV R. One can see the only difference from the true peptide is
that best estimated peptide begins with W while the true peptide begins with V S. Note
that the mass of W (186.079 Da) is within 0.5 Da of the mass of V S (186.1) and thus,
the switch can be made. Therefore, by switching W with V S, we obtain the true peptide,
and so the minimum number of switches is 1. If more than 3 switches is needed to obtain
the true peptide, we denote the minimum number of switches as 3+. In both the PepNovo
rank score and PepNovo score, the best estimated peptide may not have the same mass as















































































































































































































































































































































































































Table 7.22 The top estimated peptides from the MCMC algorithm along with their
corresponding log posterior densities for the peptide TGMSNV SK for a tolerance of
both 0.1 Da and 1.0 Da with a starting peptide of SAMYHSK.
Tolerance = 0.1 Tolerance = 1.0
Peptide Log Posterior Peptide Log Posterior
TTSSNSVAG -1.77 SAMSGGVSGA 0.10
TTSSNSVK -9.37 SAMSNVSGA -3.99
TMGSNSVK -16.78 SAMSGVGSGA -6.97
MTGSNSVK -17.12 ASMSNVSGA -8.12
TGSMNWK -18.63 ASQFGVSGA -18.17
TMGSNWK -18.76 ASQFGVSE -28.63
TMGSNSLN -20.53 ASGHVHSE -41.29
TMGSNSIN -23.92 ASGHHVSE -42.70
TGMSNWK -25.06 SAGHVHSE -49.90
TMGSNSQV -29.30 TGGHVHSE -52.84
Table 7.23 The top estimated peptides from the MCMC algorithm along with their
corresponding log posterior densities for the peptide DLV ESAPAALK for a tolerance
of both 0.1 Da and 1.0 Da with a starting peptide of DLV ESY FLK.
Tolerance = 0.1 Tolerance = 1.0
MIVLLNLAVK 16.13 EVVESLNPVK 32.61
MIVLLSPNVK 15.13 EVVESYFNK 31.97
MIVIINLAVK 5.20 EVVESLPVNK 28.44
MMHGINLAVK 3.50 EVVESLVPNK 27.67
MMHGGGILAVK 0.78 EVVESYFLE 19.11
MMHGNILAVK -6.06 EVVESYFIE 18.13
MMHGIVQAVK -8.46 EVVESYFIQ 0.59
MPVEIVQAVK -8.89 EVGATSYFIQ -19.35
MPVEVLQGLK -20.96 EVGDGSYFIQ -19.48
MPVEIVQGLK -25.78 DLGGNSYFLK -22.42
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N-terminal to the start of the de novo sequence and the C − Gap, which is the mass gap
from the C-terminal to the end of the de novo sequence. While it does provide those mass
values, it cannot detect the amino acid residues that should correspond to the mass gaps.
For example, consider the true peptide DLV ESAPAALK with a total mass of 1113.616
Da. Using the PepNovo rank score, the best estimated peptide is DNV ESLEV , which
has a mass of 885.4088 Da. Note that this mass is the sum of masses of each amino acid
residue in the sequence and does not include the mass of a water molecule and hydrogen
molecule. That is accounted for in the mass gap. The C − Gap value given is 229.029
Da implying there are amino acid residues missing from the end of the de novo sequence
whose mass should total 229.029 Da. We cannot look at the minimum number of switches;
however, we do know that a peptide with a total mass less the total mass (outside of the
tolerance) of the true protein cannot be the true peptide.
Table 7.24 displays the best estimated peptides for the PepNovo rank score, the Pep-
Novo score, and our method along with the corresponding true peptide. The minimum
number of switches is in parentheses. One can see that in most cases when using the
PepNovo rank score, the best estimated peptide does not have the correct total mass. An
advantage of our method is that all our estimated peptides will have a total mass within
a tolerance of the total mass of the true peptide. When comparing the results from the
PepNovo score and our method of using the Bayes log posterior, for peptides with shorter
amino acid sequences, the PepNovo score tends to do slightly better in estimating the true
peptide. However, for peptides with longer amino acid sequences, our method tends to do
better in estimating the true peptide. Note that one method does not necessarily work best
in every case, yet a combination of two good methods can produce an even better method.
Therefore, an avenue to explore in the future is developing a rank score method that will
















































































































































































































































































































































































































































































































































































































































































































































































Proteomics produces large amounts of spectra from mass spectrometry. Issues can arise
such as post translational modifications (PTMs), mutations, and contaminants causing the
spectra to fail to match peptides from a database. Also, there are copious microorganisms
such as prokaryotes and eukaryotes that have not been identified and therefore, using a
database search to identify these peptides would not prove useful. Of those microorganisms
that have been identified, some show evidence of PTMs, which can create complications in
the de novo sequencing when comparisons are made between the theoretical spectrum and
the observed spectrum. Thus the need for a method of identifying peptides that does not
rely on a known database and is not is affected by PTMs is evident.
Protein sequencing is another reason for the need for an accurate peptide identification
method. Protein sequencing is the method of identifying the true amino acid sequence of a
protein. Identifying an entire protein is almost impossible, and so the protein is split into
short peptides. Ergo, being able to correctly identify the amino acid sequence of a peptide
will aid in identifying the true protein sequencing.
There are limitations in the current methods for protein identification. Our method
hopes to alleviate such drawbacks of de novo sequencing and database searches. By using
a Bayesian approach, we allow prior knowledge of the peptides to help us to find the best
estimate of the true peptide. In most Bayesian approaches, the posterior distribution can be
extremely complicated and thus, Monte Carlo methods are employed. Due to the complex-
ity of our posterior density, we use MCMC simulation to obtain the posterior probabilities.
Using such MCMC algorithms allows one to approximate the target distribution, which in
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our case is the posterior distribution of the unknown peptide sequence. One advantage of
our method is that it is not dependent upon known peptides. We hope that our method will
obtain more accurate estimates of the true peptide, helping researchers in the field of pro-
teomic research and potentially aiding in identifying microbes. With the study of proteins
becoming more important in identifying early stages of diseases (most commonly cancer),
it is of great importance to be able to correctly identify these proteins. The goal is for sci-
entists to use these peptides as biomarkers for diseases. Conceivably, better identification
of peptides could aid the diagnosis of types of cancers or find better patient treatments.
8.1 FUTURE WORK
It is important to compare our results with other competing peptide identification methods
and compare more than just several examples. We plan to compare our results with PEAKS,
MASCOT, SEQUEST, and PepNovo using the same comparison technique described in
Chapter 7. We plan to look at several hundred peptides and obtain the mean number of
minimum switches it takes to obtain the true peptide for each method. When considering
peptides of different (and, in particular, longer) amino acid lengths there is good reason to
believe our method will compete favorably with others.
Noise peaks are a common problem in peptide identification, and we will explore other
thresholding methods. A common preprocessing method is binning, which reduces the
amount of data by grouping adjacent m/z values together. Hence it reduces the number
of noise peaks in the spectrum. A particular m/z and its corresponding intensity value,
within a window, is chosen to represent the group. Selecting the window width can be
quite difficult. If the window width is too large, signal peaks may be removed from the
dataset, causing the observed spectrum and theoretical spectrum to not be aligned. If the
window width is too small, then the purpose of binning is defeated; that is, the number of
noise peaks will not be reduced. One bin will be composed ofN pairs ofm/z and intensity
values and will be in the form of [(I1,m/z1), . . . , (IN ,m/zN)] where Ij is the j th intensity
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Figure 8.1 An example of how the data are reduced when using the binning method,
obtained from Monroe (2013).
value and m/zJ is the j th m/z value for j = 1, . . . , N . This group of pairs will then
be combined into the vector (I,m/z) of pairs. The intensity value I of this bin is found
using an aggregate function such as the sum or the maximum of all the N original intensity
values, and the m/z value of this bin is found by taking the median or mean of all the N
original m/z values (Bachmayer, 2007). Figure 8.1 illustrates how binning reduces the
data in a spectrum. Here a window width of 0.5 is used. The maximum intensity value of
the group is used to determine the intensity of the bin and mean of the group of m/z values
is used to determine the m/z of the bin.
The theoretical spectrum plays an important role in our method and calculating the most
accurate spectrum is key. Cleveland and Rose (2012) developed a method to identify better
peaks using a neural network, which can be used to construct a predictive model that does
not require an extensive understanding of peptide fragmentation. Better identification of
peaks will lead to a more accurate theoretical spectrum and ultimately better identification
of peptides. Recall from Chapter 3 that other ions can produce peaks in the observed
spectrum. Like our method, Cleveland and Rose (2012) concentrates on identifying signal
peaks corresponding to b and y ions; they also employ a leveraged neural network (LNN),
which is composed of two neural networks used in order to classify peaks. In the first neural
network, peak features, such as isotopologues and neutral losses, are found from the data in
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Table 8.1 Average number of peaks per spectrum classified as b− /y − ions by LNN
and PepNovo, taken from Cleveland and Rose (2012)















the spectrum. Then in the second neural network, the results from the first neural network
are leveraged as extra features in the second neural network. This process selects peaks
with higher precision and reduces the number of peaks in the spectrum, which could make
identifying the true peptide more efficient. For additional information about the LNN, see
Cleveland and Rose (2012). Table 8.1 shows the average number of peaks selected for each
spectrum by LNN and PepNovo. One can see that in almost every case, LNN produced
fewer peaks per spectrum.
An important aspect for the future development is to refine the Bayesian model. Clearly
the model can be refined by including more signal peaks b−H2O, b−NH3, y−H2O, y−
NH3, y
2, isotopic peaks, etc. This will help identify which are signal peaks and which are
noise peaks. We will further explore the prior models. Currently the cleavage model is
more uniform than that of Huang et al. (2004). A stronger prior could help concentrate the
posterior on a more restricted set of candidates.
Adapting the prior to assign probabilities to the length of the peptide is an avenue we
wish to explore. That is, we wish to include in the prior a component πk that measures the
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prior probability that the peptide length equals k, for k = 1, 2, . . .. A reasonable choice
for this prior would be a Poisson distribution. The current prior favors shorter peptide
sequences. In other words, peptides with shorter amino acid sequences have higher prior
probabilities than peptides with longer amino acid sequences. Modifying the prior could
help alleviate this problem.
We currently are using a fixed dimension parameter space and we will look into using a
reversible jump. A reversible jump allows simulation of the posterior distribution on spaces
of varying dimensions (Green, 1995). An advantage to using a reversible jump is that it
will ensure that our proposed new candidate peptide will have similar posterior strength to
our existing candidate peptide. This guarantees that the move and its reverse will both have
a good chance of being accepted by the algorithm (Hastie and Green, 2012).
Model selection using the Akaike information criterion (AIC) and the Bayesian infor-
mation criterion (BIC) will be examined (Akaike, 1974; Gelfand and Dey, 1995). Both
criteria are based, in part, on the likelihood function. AIC is a measure of the relative
goodness of fit of a statistical model given by AIC = 2k − 2 ln(L) where k is the number
of parameters in the model and L is the maximized value of the likelihood function for the
estimated model. The model with the smallest AIC value is chosen as the best model. Note
the AIC penalizes models with too many parameters, i.e., it discourages overfitting of the
model. The BIC is defined as −2 ln(L) + k ln(n) where k is the number of parameters in
the model that need to be estimated, n is the number of observations in the dataset, and
L is the maximized value of the likelihood function for the estimated model. The model
with the smallest BIC value is chosen as the best model. Like the AIC, the BIC penalizes
models with too many parameters, but the penalty term is more severe (Gelfand and Dey,
1995; Burnham and Anderson, 2002; Rodríguez, 2013). With all the variations to our al-
gorithm that we plan to explore, there will be several models defined. Therefore, it will be
important to use good criteria to select the best model.
The Bayesian framework and model are in place for practical usage. With some further
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